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Abstract 
Vitamin D deficiency has been traditionally associated with bone disorders; recent studies, 
however, show a relationship to several non-skeletal diseases such as autoimmune diseases, 
rheumatoid arthritis, hypertension, diabetes mellitus, cardiovascular diseases and common 
cancers. As a result, there has been an increasing global concern on the role of vitamin D in 
human health. 
Vitamin D occurs as a number of metabolites/analogues that vary in their biological 
functions. Vitamin D3 (D3) and 25-hydroxyvitamin D3 (25(OH)D3) are considered more 
potent than vitamin D2 (D2) and 25-hydroxyvitamin D2 (25(OH)D2). The 1,25-
dihydroxyvitamin D metabolites (1,25(OH)2D3 and 1,25(OH)2D2) are the most active forms 
that are responsible for bone health. The 24,25-dihydroxyvitamin D metabolites 
(24,25(OH)2D3 and 24,25(OH)2D2) are responsible for intramembranous and endochondral 
bone formation, and bone fracture repair. The biological roles of sulfated 
analogues/metabolites, vitamin D-Sulfate (D3-S and D2-S) and 25-hydroxyvitamin D-Sulfate 
(25(OH)D3-S and 25(OH)D2-S), are unclear to date, probably due to the lack of sufficiently 
sensitive assay methods. It has been suggested, however, that sulfated forms are storage 
forms of the non-sulfated forms, and may have similar potencies. The major circulating form 
is 25(OH)D3, with a long half-life, and is therefore considered as the principal biomarker of 
vitamin D status. However, considering the varied biological roles of vitamin D 
analogues/metabolites listed above, it is desirable to assay as many as possible using a 
sensitive and specific method. 
Milk is an important source of vitamin D for various risk populations, including infants. 
When mothers are unable to breastfeed their infants, pasteurised donor human milk is the 
most effective alternative source of nutrition. Vitamin D is potentially sensitive to high 
temperatures and pasteurisation is a thermal procedure potentially responsible for vitamin D 
degradation. No studies on the impact of pasteurisation on vitamin D content in breastmilk 
have yet been reported. 
There are only few vitamin D assay methods available for unfortified milk. Among them, 
liquid chromatography-tandem mass spectrometry (LC-MS/MS) has been demonstrated to be 
the best technique in terms of sensitivity and specificity compared with other methods. 
However, using LC-MS/MS for vitamin D is a challenging task because vitamin D 
analogues/metabolites have poor MS/MS detectability due to their low ionisation in 
atmospheric ionisation sources such as electrospray and chemical ionisation. Although there 
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are eight major analogues/metabolites of vitamin D in biological fluids, currently available 
LC-MS/MS methods are capable of quantifying only four of these in milk; the 
dihydroxylated and sulfated forms are not quantified. Furthermore, current methods do not 
distinguish the major circulating form, 25(OH)D3, from its inactive epimeric form, resulting 
in an over-estimation of 25(OH)D3. 
This thesis describes the development and validation of an LC-MS/MS method for the 
quantitative analysis of eight major forms of vitamin D in milk: D2; D3; 25(OH)D2; 
25(OH)D3; 24,25(OH)2D2; 24,25(OH)2D2D3; 1,25(OH)2D2 and 1,25(OH)2D3. Protein 
precipitation was compared with the commonly used saponification method for extraction of 
vitamin D from milk and found to be simpler and more effective. A systematic optimisation 
of the pre-column derivatisation procedure using 4-phenyl-1,2,4-triazoline-3,5-dione (PTAD) 
was performed to enhance the ionisation efficiencies thereby increasing the sensitivities of all 
vitamin D compounds. Chromatography was also optimised to reduce matrix effects in the 
MS/MS detector, and co-eluting stable isotope labelled internal standards were used for the 
calibration of each analogue/metabolite to eliminate matrix effects. The metabolite 25(OH)D3 
and its epimer were chromatographically separated to prevent over-estimation of vitamin D 
status. The method was validated: detection limits ranged from 0.2 to 0.4 femtomols, 
repeatability standard deviations ranged from 6.30 to 13.5%, and the recoveries ranged from 
88.2 to 105%. 
The validated method was then applied to assay for vitamin D compounds in human, cow, 
mare, goat and sheep milk samples and was also used to evaluate the effect of pasteurisation 
on the content of vitamin D in breastmilk. Pasteurisation resulted in a significant reduction (P 
< 0.05) in the detected vitamin D compounds and the losses ranged from 10 to 20%.  
During the initial method development, an attempt was made to include sulfated vitamin D 
compounds, D2-S; D3-S; 25(OH)D2-S and 25(OH)D3-S. However, the method failed to detect 
sulfated forms in milk, except for traces of 25(OH)D3-S. Therefore, an LC-MS/MS method, 
specific for sulfated forms, was developed. A comparative evaluation showed that, for 
sulfated forms, the ionisation efficiencies of underivatised forms in negative ion mode 
electrospray ionisation (ESI) were superior to those of derivatised forms with PTAD in 
positive ion mode ESI. Therefore, underivatised D-S compounds were used with negative MS 
mode, in an LC-MS/MS method similar to the method for non-sulfated forms. The method 
was then fully validated: detection limits ranged from 0.20 to 0.28 femtomol, repeatability 
standard deviations ranged from 2.8 to 10.2%, and recoveries ranged from 81.1 to 102%. The 
validation and application of this sulfated method was undertaken for both human milk and 
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serum. All four sulfated vitamin D analogues/metabolites were quantifiable in serum, and 
three in milk. 
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1 Chapter 1. Literature review 
 
1.1 Foreword 
Chapter 1 reviews the analytical methods used to quantify vitamin D, and within this context 
introduces vitamin D, its many forms and its metabolism. This review employed a 
comprehensive search of the most used vitamin D methods for all applications. Particular 
emphasis was given to sample preparation methods and the different forms of vitamin D 
measured across different fields of applications such as biological fluids, food and 
pharmaceutical preparations. This revision compared and critically evaluated a wide range of 
approaches and methods, and then used this comparative critical evaluation to formulate the 
best possible vitamin D assay method that is the subject of the subsequent chapters of this 
thesis. The content of this comprehensive review has been published as a review article in the 
journal Bioanalysis 5 (24): 3063-78 (2013). This article is presented in this chapter, in a 
slightly altered format to fit with the style of this thesis. Permission was granted from the 
publisher to reproduce the work in the thesis. Some additional information such as the 
introduction of sulfated forms of vitamin D is added. Tables 1 and 2 have been updated, to 
include new analytical methods from 2013 to 2016. The research hypothesis and aims of this 
thesis are also included. 
 
1.2 Introduction 
Vitamin D insufficiency and its deficiency in human populations has been demonstrated to be 
of significant concern and has become a very important health issue (1). Vitamin D defi-
ciency is not only related to muscle weakness and osteomalacia, but has also been associated 
with cardiovascular disease, cancer, autoimmune diseases, diabetes mellitus and hypertension 
(2-5). Furthermore, newborn babies may be affected in their normal growth and development, 
putting them at risk of long-term physical deficits (6). Vitamin D status is usually evaluated 
by determining the levels of the metabolite 25-hydroxyvitamin D (25[OH]D), the major 
circulating form, which is considered the most important biomarker among the many forms 
of this vitamin in plasma or serum (7). Early detection of vitamin D deficiency is of key 
importance in order to identify affected individuals who can then receive adequate and 
appropriate treatment. As a result, many analytical methods based on a variety of techniques 
have been reported for the assay of vitamin D and its metabolites, or analogues, in complex 
matrices, especially in biological fluids. Subsequently, many reviews have been published on 
the topic of vitamin D assay methods. However, most of the reviews published in recent 
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years have focused on the measurements in biological fluids such as serum or plasma using 
LC–MS (8-12). While the majority of vitamin methods published have focused on LC–MS, 
this chapter discusses all methods, including immunoassays, HPTLC, NMR and Raman 
scattering, since LC–MS still remains an inaccessible instrument for many analytical 
laboratories. In addition, we have included measurements in all matrices including food, 
plants, biological fluids and pharmaceutical preparations. Emphasis was given to various 
forms of vitamin D that were measured, and the various extraction and sample preparation 
methods employed for this purpose. In general, the development of vitamin D methodologies, 
using a variety of techniques and in various fields (e.g., biological fluids, foods and 
pharmaceutical products), has been undertaken in isolation. We believe that a chapter with all 
vitamin D methods that compares and critically evaluates a wide range of approaches will 
provide a valuable addition to the literature and will enable the reader to access developments 
across a number of applications and to select or develop the optimal method for their 
particular application. For this reason, we have divided all methods into common sections: 
sample preparation, separation and detection, and quantification, in order that the reader can 
select the best option from each section and tailor a new method of analysis. The comparisons 
and evaluations were undertaken for each of the above sections to render this task easier. Our 
search included comprehensive databases: ISI Web of Science®, Scifinder®, Science Direct, 
Scopus and PubMed, for all vitamin D methods published recently. The search word used 
was ‘vitamin D’ and then refined using key words such as ‘quantitation’, ‘determination’ and 
‘methods’. Approximately 120 articles were found in total, but only some 90 are included 
here because others comprise studies where the methods used were not described in detail, 
thus not enabling us to review them fully in this chapter. 
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1.3 Forms of vitamin D and its metabolites 
Vitamin D has two major forms, cholecalciferol (vitamin D3) and ergocalciferol (vitamin D2) 
(Figure 1).  
 
 
Figure 1. Different forms of vitamin D. 
 
In animals, vitamin D3 is obtained from food or by photosynthesis in the skin, formed from 
UV irradiation (UV-B: 290– 315 nm) of 7-dehydrocholesterol in the skin. In plants, vitamin 
D2 is produced by the irradiation of ergosterol. Both vitamins D2 and D3 are biologically 
inactive. In humans, they are metabolized in the liver to calciferol (25-hydroxyvitamin D2 and 
25-hydroxyvitamin D3, collectively known as 25(OH)D). Vitamin D that is not metabolized 
in the liver is stored in the adipose tissue and skeletal muscle, then released during vitamin D 
deprivation. The major circulating form of vitamin D is 25(OH)D, which is then transported 
to the kidney where it is hydroxylated to its hormonal and biologically active form, calcitriol 
(1,25-dihydroxyvitamin D, also called 1a,25-dihydroxyvitamin D, [1,25(OH)2D]) or the form 
considered inactive, 24,25-dihydroxyvitamin D [24,25(OH)2D] (Figure 2), depending on the 
calcium and phosphorus requirements of the animal (13).  
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Figure 2. Biosynthesis and metabolism of vitamin D3 in humans. 
 
Although 24,25(OH)2D has been originally considered to possess little or no activity, other 
than serving to divert the metabolism of 25(OH)D away from 1,25(OH)2D, some studies 
indicate that it is a functionally independent hormone that plays a crucial role in 
intramembranous and endochondral bone formation and in the repair of bone fractures (13). 
The process of the conversion to the biologically active forms of vitamin D2 and D3 was 
evident by the lag time between the administration and the appearance of a physiological 
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response. In animals, the potency of vitamin D2 was found to be higher than that of vitamin 
D3 when the animal is nocturnal and/or when its diet is primarily plant-based (13). In 
humans, most research has been carried out with vitamin D3 rather than vitamin D2, with the 
former found to be more efficacious than the latter at raising serum vitamin D concentrations 
(14). In plasma, all forms of vitamin D are bound to vitamin D-binding protein (DBP), 
however, the binding affinity of 1,25(OH)2D is tenfold less than that of 25(OH)D (with both 
vitamin D2 and D3). Although the dietary forms are mainly the non-hydrolyzed forms, there 
may be small amounts of 25(OH)D in some foods that can be absorbed far more easily by the 
body. In some disease states 25(OH)D is the more effective form of supplementation due to 
its ease of absorption. The normal concentration range of plasma 25(OH)D is 10 to 40 
ng/mL. Unlike with photosynthesized vitamin, with dietary intake levels can rise to over 400 
ng/mL, leading to vitamin D toxicity. The normal plasma concentration of 24,25(OH)2D in 
humans ranges from 1 to 4 ng/mL, while that of the potent form, 1,25(OH)2D, is maintained 
within the range 25 to 70 pg/mL by reciprocal changes in the rates of synthesis and 
degradation at the cellular level (13).  
Currently, 25(OH)D (25(OH)D2 and 25(OH)D3 collectively) is considered to be the best 
indicator of vitamin D status in either serum or plasma because this metabolite has been 
demonstrated to have a half-life much longer and a circulation concentration approximately 
1000- times larger than 1,25(OH)2D, which allows a precise estimation of vitamin D status 
from both dietary intake and UV irradiation (15). In addition, 25(OH)D is produced based on 
its substrate concentration, which is different from 1,25(OH)2D that is limited by the calcium 
requirements of each individual (13, 16).  
Vitamin D can be also found as water-soluble (sulfated) forms. Little clinical and nutritional 
attention have been given to these conjugated forms. While a few proponents claim their vital 
roles in humans, mainly on semi-scientific websites (17, 18), a clear evidence is still out. 
Studies suggest that non- and sulfated forms possess equivalent potencies and also that 
sulfated forms could be storage forms of non-sulfated forms (19-21). The biosynthesis of 
sulfated forms still remains to be elucidated (19, 22); however, it has been found that vitamin 
D3-Sulfate (D3-S) is formed in the skin in a similar photochemical process of its non-
conjugated form. It was confirmed by the presence of 7-dehydrocholesterol-sulfate (7-DHC-
S) in human skin (19). While there is no conclusion about the specific role of each sulfated 
form, D3-S has been reported to increase calcium transportation in young rats (23). The 
metabolite 25-hydroxyvitamin D3-sulfate (25(OH)D3-S) could be an important vitamin D 
biomarker, as its levels in human circulation seems to exceed those of its non-conjugated 
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form (19, 22). Vitamin D2-Sulfate (D2-S) has been shown to have an efficient antirachitic 
activity in rats (24). There are no reports of the metabolite 25-hydroxyvitamin D2-Sulfate 
(25(OH)D2-S) in human or animal biological fluids. The lack of research in to water soluble 
(sulphated) forms of vitamin D could be due to the lack of analytical methods available to 
quantify them. 
While there are more than 50 vitamin D metabolites, clinical studies has primarily focused on 
the assessment of 25(OH)D status (25). However, it is still controversial whether the 
measurement of only 25(OH)D provides sufficient information to link vitamin D with many 
other non-skeletal disorders such as the aforementioned diseases in the introduction section 
(25, 26). Hence, the capability to specifically measure different vitamin D forms is highly 
valuable to investigate clinical disorders that are associated with vitamin D deficiency and/or 
vitamin D metabolic dysfunction (25). 
Recently, the detection of epimeric forms of 25(OH)D and 1,25(OH)2D in infant, paediatric 
and adult populations has raised the question as to whether these C3-epimers can/should be 
measured (27). Studies have found that all vitamin D metabolic products can be epimerized 
(27) and 3-epi-1,25(OH)2D3 is also capable of binding to the vitamin D receptor (28). The 
epimerisation routes for 25(OH)D and 1,25(OH)2D are shown in Figure 3 (29).  
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Figure 3. Epimerization routes for 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3. E: 
The epimeric centre. Adapted from (29). 
 
3-Epi-25(OH)D3 and 3-epi-1,25(OH)2D3 are considered inactive or relatively less active in 
terms of their physiological effects, therefore, collective measurement of the vitamin D forms 
and their epimers may contribute to an overestimation of the vitamin D activity and 
detrimentally affect the outcome of clinical studies (28). Recent analytical methods have 
separated the epimers using special columns with LC–MS/MS separation and detection, 
rather than by measuring the total using techniques such as immunoassay and the more usual 
LC methods (27).  
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The main form of vitamin D present in plant-based foods dried in sun or under UV light is 
vitamin D2 formed by the irradiation of ergosterol. However, a recent study found that 
cholesterol containing plant foods such as the Solanaceae family are able to produce vitamin 
D3 (30). The major form in animal based foods such as cod liver oil, oily fish, eggs and cow’s 
milk products, is vitamin D3 (31). However, human and cow’s milk both contain small 
amounts of other metabolites such as 24,25(OH)2D and 1,25(OH)2D3 (32). It was found that 
25(OH)D3 is absent in cow’s milk products (33). In pharmaceutical preparations, in addition 
to vitamin D2 and D3, 1,25(OH)2D3 and its analogues, 1α-hydroxyvitamin D3 (1[OH]D3) have 
also been used for the treatment of diseases such as osteoporosis (34). In general, vitamin D 
analysis in foods has been undertaken on fortified foodstuffs, therefore mainly concentrating 
on vitamin D3 and vitamin D2. 
 
1.4 Analytical methods 
1.4.1 Sample preparation 
Sample preparation is the first and the critical stage of method development as it directly 
impacts on the accuracy of the analytical method. The extraction (from the matrix) of the 
vitamin is a crucial step, as it cannot be assessed by the validation process. While the 
recovery parameter estimates the accuracy in terms of how much of the added vitamin is 
recovered, it does not indicate whether the vitamin is completely extracted from the matrix. A 
recent study that compared six different vitamin D assay methods concluded that inadequate 
release of the vitamin from the DBP, in some of the methods, was the main reason for the 
high between-method variabilities they observed (35). In this comparison, most methods 
performed poorly when such protein levels are high in conditions such as pregnancy.  
The sample clean-up step has special significance in chromatographic methods coupled with 
MS: adequate sample clean-up not only protects the chromatographic columns, but also 
reduces matrix effects from co-eluting substances during the ionisation process. Particularly 
for vitamin D compounds in biological fluids or foodstuffs, their very low concentrations 
demand adequate sample-preparation methods in order to achieve the best sensitivity. 
Sample preparation, in this chapter, is divided into extraction, clean-up and derivatisation 
steps, all processes that are involved prior to separation and detection. Table 1 summarizes 
each of these steps, along with the forms of vitamin D measured in different matrices, in 
analytical methods.  
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          Table 1. Summary of sample preparation methods used in the analysis of vitamin D. 
 
 
 
 
 
Vitamin D analogues Sample Extraction  Clean up Derivatisation  Refs.  
25(OH)D3, 25(OH)D2 
1α25(OH)2D3, 1α25(OH)2D2 
24,25(OH)2D3  
 
Serum PP – ACN LLE - K2HPO4:MTBE 
SPE - RP, ACN 
PTAD (36) 
 
25(OH)D3, 25(OH)D2 
3-epi-25OHD3, 24R,25(OH)2D3 
 
Serum PP – ACN 
 
Online SPE - RP, MeOH:H2O 
 
------- (37) 
25(OH)D3, 25(OH)D2 
3-epi-25OHD3 
 
Serum PP – ZS, MeOH 
 
LLE – HEX:EtOAc   
 
------- (38) 
1α25(OH)2D3 
 
Serum PP – ACN Online SPE - RP, MeOH:ACN:H2O  ------- (39) 
25(OH)D3, 25(OH)D2 Serum PP – ACN Online SPE - RP, MeOH:H2O 
 
------- (40) 
1,25(OH)2D2 
  
Serum 
 
PP – ACN 
 
SPE - RP,  TBME 
(96-well plate) 
 
------- (41) 
25(OH)D3, 25(OH)D2 
 
Serum PP – ACN Online SPE 
(96-well plate) 
 
------- (42) 
25(OH)D3, 25(OH)D2  
1α25(OH)2D3, 24,25(OH)2D3 
 
Serum PP - MeOH:ACN 
 
SPE - RP, ACN:IPA:FA PTAD (43) 
25(OH)D3, 25(OH)D2 Serum  
 
PP – ACN ------- ------- (44) 
25(OH)D3, 25(OH)D2 Serum 
 
PP – ACN ------- ------- (45) 
25(OH)D3, 25(OH)D2 
 
Serum PP – ACN -------  (46) 
1α25(OH)2D3, 1α25(OH)2D2 
 
Serum PP – ACN 
IDS antibody 
 
Alcohol 
SPE - RP, Alcohol 
------- (47) 
25(OH)D3, 25(OH)D2 
 
Serum PP – ACN 
(96-well-plates) 
 
------- ------- (48) 
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Table 1 (continued). 
 
Vitamin D analogues Sample Extraction  Clean up Derivatisation  Refs.  
25(OH)D3, 25(OH)D2 
 
Serum PP – ACN 
(96-well-plates) 
 
LLE – H 
(96-well-plates) 
 
------- (49) 
25(OH)D3, 25(OH)D2 Serum PP – ACN 
(96-well-plates) 
 
------- 
 
------- (50) 
25(OH)D Serum  PP - ACN (RIA) 
PP - Surfactant:EtOH (CLIA) 
 
------- ------- (51) 
25(OH)D3, 25(OH)D2 Serum PP – EtOH SPE - RP, EtOAc:H  
PC – CN, IPA:H 
 
------- (52) 
25(OH)D 
 
Serum PP - EtOH   LLE - HEX:DCM ------- (53) 
25(OH)D3 Serum PP – EtOH (ELISA)  
 
------- ------- (54) 
D3 Serum PP - MeOH 
 
------- ------- (55) 
25(OH)D3, 25(OH)D2 Serum PP – MeOH SPE - RP, MeOH:H2O 
(Automated) 
 
------- (56) 
D2, D3, 25(OH)D2, 25(OH)D3  
 
Serum PP – ACE ------- ------- (57) 
D3, D2, 25(OH)D3, 25(OH)D2, 
1α25(OH)2D2 1α25(OH)2D3, 3-epi-
25(OH)D3, 3-epi-25(OH)D2 
Serum PP - MeOH:IPA:FA 
 
LLE - DCM:H ------- (58) 
 
25(OH)D3, 25(OH)D2 
 
Serum PP - MeOH:ACN SPE - RP, MeOH ------- (59) 
25(OH)D3, 25(OH)D2  
3-epi-25(OH)D3 
 
Serum PP - MeOH:IPA 
 
LLE - HEX ------- (60) 
25(OH)D3, 25(OH)D2 
3-epi-25(OH)D3, 1α(OH)D3  
Serum PP - MeOH:IPA 
 
LLE - HEX:DCM 
SPE - silica, E:HEX 
------- (29) 
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Table 1 (continued). 
 
Vitamin D analogues Sample Extraction  Clean up Derivatisation  Refs.  
25(OH)D3, 25(OH)D2 
3-epi-25OHD3 
 
Serum PP - ACN:H2O:ZS SPE - RP, ACN:ACE 
(96-well plate)   
------- (28) 
25(OH)D3, 25(OH)D2 
 
25(OH)D3, 25(OH)D2                             
3-epi-25OHD3 
 
Serum 
 
Serum  
------- 
 
PP - ACN:MeOH 
LLE - HEX:EtOAc 
 
SPE – MeOH 
------- 
 
------- 
(61) 
 
(62) 
D3 Serum ------- LLE - MTBE 
LLE – MTBE 
SPE - RP – MeOH 
(96-well plate)      
 
PTAD (63) 
1,25(OH)2D2, 1,25(OH)2D3 
 
Serum -------- 
 
SPE – Chromabond XTR, PrOH:HEX   
SPE – silica, PrOH:HEX  
 
 
Amplifex 
PTAD 
(64) 
D2, D3, 25(OH)D2, 
25(OH)D3,  
24,25(OH)2D3, 1,25(OH)2D2, 
1,25(OH)2D3 
 
25(OH)D3, 24,25(OH)2D3  
 
Serum 
 
 
 
 
Serum 
------- 
 
 
 
 
PP – ZS:MeOH 
SPE – ACN:H2O 
 
 
 
 
LLE – HEX: MTBE 
------- 
 
 
 
 
DMEQ-TAD 
(65) 
 
 
 
 
(66) 
25(OH)D3, 25(OH)D2 Serum  PP – MeOH 
 
 
LLE - HEX 
 
------- (67) 
25(OH)D3,  
3-epi-25(OH)D3 
 
Serum PP – EtOH:MeOH:H2O LLE - HE 
(96-well plate)  
 
------- (68) 
      
1α25(OH)2D3, 1α25(OH)2D2 
 
Serum PP - MeOH:ACN 
 
SPE - monoclonal anti-1α25(OH)2D, 
EtOH 
 
PTAD (69) 
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Table 1 (continued). 
 
Vitamin D analogues Samples Extraction Clean up Derivatisation Refs. 
25(OH)D3,  
3-epi-25(OH)D3 
 
 
Serum or murine skin -------- 
 
SPE – ACN:MeOH 
 
PTAD (70) 
24,25(OH)2D3, 25(OH)D3 
 
Serum or brain  PP - ACN 
 
-------  PTAD (71) 
D2, D3, 25(OH)D2, 
25(OH)D3,  
24,25(OH)2D3, 
1,25(OH)2D2, 
1,25(OH)2D3 
 
Serum or plasma PP – MeOH:FA SPE - Online -------  (72) 
25(OH)D3, 25(OH)D2 Serum or plasma PP – MeOH 
 
LLE - H 
 
------- (73) 
25(OH)D3, 25(OH)D2 Serum or plasma SN – MeOH:NaOH  
(96-well plate) 
 
LLE - H 
(96-well plate) 
------- (74) 
25(OH)D3, 25(OH)D2 
1,25(OH)2D3, 
1,25(OH)2D2, 
24,25(OH)2D3 
 
Plasma PP - ACN  
 
SPE - RP, ACN:EtOAc 
LLE - EtOAc-H2O 
PTAD (75) 
25(OH)D3, 25(OH)D2  
 
Plasma PP - MeOH  
 
SPE - Online ------- (73) 
 
25(OH)D3-S 
 
Plasma 
 
PP - ACN 
 
SPE – Oasis-HLB, MeOH 
 
------- 
 
(21) 
25(OH)D3 
 
 
25(OH)D2, 25(OH)D3 
Plasma 
 
 
Plasma  
PP – EtOH 
 
 
PP – MeOH:H2O:DIOX 
SPE - RP, MeOH 
LLE - HEX 
 
LLE – HEX 
------- 
 
 
------- 
(76) 
 
 
(77) 
25(OH)D Plasma PP - ACN (RIA) ------- ------- (78) 
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  Table 1 (continued). 
 
Vitamin D analogues Sample Extraction  Clean up Derivatisation  Refs.  
25(OH)D2, 25(OH)D3 Plasma PP – MeOH:ACN:ZS 
 
------- ------- (79) 
25(OH)D3, 1α25(OH)2D3 
24,25(OH)2D3, 4β25(OH)D2 
 
Plasma 
 
PP - ACN 
 
LLE - EtOAc 
 
PTAD (80) 
25(OH)D3, 25(OH)D2 Plasma PP - EtOH:BHT LLE - ISO-OCT:C ------- (81) 
 
D3, D2, 25(OH)D3, 25(OH)D2 
 
Plasma SN – MeOH:AS:KOH 
 
LLE – H ------- (82) 
25(OH)D3, 3-epi-25(OH)2D3 
 
Dried blood spots PP - MeOH SPE – RP, EtOAc PTAD (83) 
25(OH)D3, 25(OH)D2 Dried blood spots PP – MeOH LLE - HEX ------- (84) 
 
25(OH)D3, 3-epi-25(OH)D3 Dried blood spots ------- ------- PTAD 
DAPTAD 
DEAPTAD 
QTAD 
 
(85) 
 
25(OH)D3 Dried blood spots PP - MeOH ------- DAPTAD 
 
(86) 
25(OH)D3, 24,25(OH)2D3 Urine -------- SPE - Oasis® HLB, 
MeOH:H2O 
 
DAPTAD 
 
(87) 
25(OH)D3 Saliva PP – ACN SPE - RP, EtOAc 
 
PTAD (88) 
25(OH)D3 Swine tissue PP - MeOH 
 
SPE - RP, MeOH ------- (89) 
D2, D3, 25(OH)D3,  
1,25(OH)2D3 
 
Mouse brain ------- LLE – DCM:MeOH ------- (90) 
D3, 25(OH)D3  
 
Porcine tissues SN – NaAS:KOH:EtOH LLE – PrOH:H 
SPE – silica, PrOH:H 
PTAD (91) 
D3 
 
Spinach leaves SN - KOH:EtOH:AS 
 
SPE - silica, IPA:H ------- (30) 
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Table 1 (continued). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
 
 
 
 
 
 
Vitamin D analogues Sample Extraction  Clean up Derivatisation  Refs.  
D2-S, D3-S, 25(OH)D2-S,  
25(OH)D3-S 
Milk/Serum PP - ACN ------- -------  
(92) 
 
D2, D3, 25(OH)D2, 25(OH)D3,  
3-epi-25(OH)D3, 24,25(OH)2D2, 
24,25(OH)2D3, 1,25(OH)2D2, 
1,25(OH)2D3 
 
 
Milk 
 
PP - ACN 
 
LLE – HEX:DCM 
 
PTAD 
 
(93) 
D3 
 
Beverage SN – KOH:EtOH:AS LLE – E:PE 
PC - silica, 
MeOH:ACN  
 
------- (94) 
D3, D2 
 
Food SN - EtOH:KOH LLE - H  
SPE - silica, MeCl:IPA 
 
------- (95) 
D3, 25(OH)D3 
 
Food SN – PY:EtOH:KOH 
 
SPE - silica, IPA:DCM 
PC - silica-NH2, 
IPA:HEX 
 
------- (96) 
D3, D2 
 
Food SN - Alcohol:PA:KOH 
 
LLE - HEX:BHT ------- (97) 
D3 
 
Food SN - KOH:AS LLE - E:PE ------- (98) 
D3, D2 
  
Food SN - NaAS:MeOH:KOH 
 
LLE - E:P 
 
------- (99) 
D3 
 
Food PP - MeOH:ISO-OCT:H2O ------- PTAD (100) 
D3 Food SN – EtOH:KOH:AS LLE – HEX:BHT 
SPE – silica, 
HEX:EtOAc 
 
------- (33) 
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Table 1 (continued). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vitamin D analogues Sample Extraction  Clean up Derivatisation  Refs.  
D3 
 
Supplement ------- SPE - NH2, EtOAc ------- (101) 
D3 
 
Supplement ------- ------- ------- (102) 
D3 Pharmaceuticals PP - ACN:MeOH 
 
------- ------- (103) 
Abbreviations:  ACE, acetone;  ACN, acetonitrile;  AS, ascorbic acid;  BHT, butylated hydroxytoluene;  C, chloroform; 
CYHA, cyclohexane;  DAPTAD,  4-(4-dimethylaminophenyl)-1,2,4-triazoline-3,5-dione;  DCM, dichloromethane;   
DEAPTAD,  4-(4-diethylaminophenyl)-1,2,4-triazoline-3,5-dione; DIOX, dioxane;  DMEQ-TAD,  4-[2-(6,7-dimethoxy-4-
methyl-3,4-dihydroquinoxalinyl-)ethyl]-1,2,4-triazoline-3,5-dione; E, ether;   EtOAc, ethyl acetate;  EtOH, ethanol; FA, formic 
acid;  H, heptane;   HEX, hexane; H2O, water;  IPA, isopropanol;   ISO-OCT, isooctane;  LLE, liquid-liquid extraction; KOH, 
potassium hydroxide;  K2PO4, potassium phosphate dibasic;   MeCl, methylene chloride; MeOH, methanol; MTBE, methyl t-
butyl ether;  NH2, amino column; P, pentane;  PA, pyrogallol acid; PC, preparative column;  PE, petroleum ether; PTAD, 4-
phenyl-1,2,4-triazoline-3,5-dione;  PrOH, propanol; PY, pyrogallol; NaOH, sodium hydroxide;  NaAS, sodium ascorbate; 
NH2, amino column;  QTAD,  4-(6-quinolyl)-1,2,4-triazoline-3,5-dione; SPE, solid phase extraction; ZS, zinc sulphate. 
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A step prior to sample preparation (sample collection) that deserves special mention here is 
the use of DBS. In recent years DBS has been used as a sample collection method, instead of 
the usual heparinised tubes, especially in neonatal monitoring where the sample size available 
is very low (104, 105). However, Kvaskoff et al. have recently investigated the implications 
of DBS sampling on quantitation and reported that factors such as gradient distribution of the 
vitamin on paper, and thus the hole punch position, paper type and blood spot volume, can 
add variability to the analysis of 25(OH)D (106). 
 
1.4.1.1 Extraction 
The protein and lipid portions of biological fluids or foodstuffs containing vitamin D 
compounds comprise a large group of compounds such as triglycerides, phospholipids and 
DBPs. The physicochemical properties of these molecules make them a promising potential 
source of interference. As vitamin D compounds in biological fluids or foodstuffs are bound 
to proteins and/or lipids, these chemical bonds should be broken to liberate the analyte (32, 
107). Hence, it is essential to use rigorous procedures to release vitamin D compounds from 
these macromolecules and concentrate them. Two approaches have been extensively applied 
to remove proteins and lipids. One is deproteinisation or protein precipitation (PP), used 
mainly for biological fluids where the vitamin is released from the proteins by denaturing the 
protein. The other one is saponification (SN), used mainly for foodstuffs where the vitamin is 
released by hydrolysis of the ester group formed between the hydroxyl groups of the vitamin 
and carboxylic acid groups of the proteins. 
 
1.4.1.2 Protein precipitation 
PP is frequently used to remove proteins from biological fluids. The methodology is based on 
mixing the sample with aqueous or organic solvents to precipitate out the proteins by dena-
turation. Subsequently, the precipitated proteins are removed by centrifugation, the 
supernatant removed by evaporation and the residue reconstituted in a suitable solvent 
depending on the analytical method used. As shown in table 1, acetonitrile is the most 
commonly used precipitant in PP (21, 36, 37, 39-42, 44-51, 75, 78, 92, 93, 108, 109). Other 
precipitants such as acetone, dioxane, ethanol and methanol have also been used with 
biological fluids (52-57, 73, 76, 83, 84, 89). Some precipitant solutions based on mixing 
solvents such as acetonitrile, methanol, ethanol, isopropanol and aqueous zinc sulfate have 
also been used for the extraction of vitamin D compounds (28, 29, 43, 58-60, 67, 69, 77, 79, 
81, 103, 110). In some cases, the precipitant solvent is mixed with a nonpolar extracting 
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solvent (111). As shown in table 1, some methods have not used either PP or SN extractions 
(61, 63). Some of these were supplementary preparations, which did not need extraction (101, 
102). With radioimmunoassay, acetonitrile is usually used to extract the 25(OH)D (51, 78) 
while a recent ELISA method used ethanol for the same procedure (54). With 
chemiluminescence enzyme immunoassay, 25(OH)D is dissociated from protein by a buffer 
containing 10% ethanol and surfactant (51). Commercially available immunoassay kits use 
proprietary techniques to displace the vitamin from the binding protein. An important 
innovation in routine analysis has been the introduction of 96-well plates for PP whereby 
many samples can be prepared simultaneously (48-50). Although simple and convenient, a 
major drawback of PP is that the extract is not very clean, containing a considerable amount 
of impurities from the matrix. Consequently, this phenomenon may lead to ion suppression in 
LC–MS as well as poor selectivity. 
 
1.4.1.3 Saponification (SN) 
SN is commonly used with foodstuffs. Based on well-established principle of alkaline hydro-
lysis, this procedure consists of mixing the sample with potassium hydroxide in ethanol or 
methanol solution, and heating to approximately 80°C for approximately 1 h. SN can also be 
performed cold, overnight at room temperature with magnetic stirring (32). As shown in table 
1, the non-saponifiable portion containing the vitamin is then extracted using a nonpolar 
solvent such as ethyl ether, pentane, petroleum ether, heptane or hexane. Subsequently, the 
organic phase is removed by evaporation and the residue reconstituted in a suitable solvent 
depending on the analytical method used.  
Potassium hydroxide in ethanol or water solution, containing ascorbic acid as the antioxidant 
to reduce the instability of vitamin D compounds during the SN procedure, has been the most 
common option of SN for foodstuffs (30, 98, 112, 113); some methods did not use an 
antioxidant (95, 114). When methanol was used instead of ethanol, no significant differences 
were observed (82, 99). Some methods have employed pyrogollol as the antioxidant (96, 97).  
Although SN is normally used with foodstuffs, Hymoller et al. and Hoofnagle et al. have 
unusually applied this approach for plasma/serum samples; in this procedure, alkalinisation 
was performed with sodium hydroxide and was found to be efficient for their purpose (74, 
82). Ethanolic KOH is preferred to aqueous KOH in the saponification of dairy products 
because it mixes well with fat and prevents formation of emulsions (32). Disadvantages of 
the SN procedure are the loss of vitamin during SN and use of carcinogenic organic solvents. 
Also, interfering substances are not completely removed.  
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1.4.1.4 Sample clean-up 
After the release from matrix components such as protein and fat the sample requires further 
clean-up in order to remove other interfering substances prior to the separation and/or 
detection. Sample clean-up often improves the sensitivity and selectivity of the assay.  
 
1.4.1.5 Liquid-liquid extraction (LLE) 
LLE is the most common clean-up procedure used for the analysis of vitamin D compounds. 
In vitamin D analysis LLE consists of adding and mixing of a relatively less polar, water 
immiscible solvent to extract the hydrophobic vitamin D compounds. The organic layer is 
then separated, the solvent removed and the sample reconstituted in a suitable solvent 
depending on the subsequent analytical technique used.  
As shown in table 1, LLE in vitamin D assays has commonly employed solvents such as hex-
ane, heptane, ether, ethyl acetate, methyl t-butyl ether, dichloromethane, cyclohexane, 
isooctane, chloroform, pentane or mixtures of nonpolar solvents. Usually, LLE has been 
performed manually where several stages of solvent transfers are necessary. Automated 
multi-well plate methods have recently been introduced for simultaneous LLE to improve the 
throughput of the assay (49, 63, 74, 110). Although LLE is a relatively simple and 
inexpensive sample clean-up procedure, practical difficulties remain, such as the handling of 
emulsion formation and the use of hazardous solvents.  
 
1.4.1.6 Solid phase extraction (SPE) 
SPE has also been widely used for analysis of vitamin D, as shown in table 1. In vitamin D 
analysis, the SPE procedure is usually conducted using reversed phase cartridges. However, 
polar sorbents where interactions between compounds and stationary phases may occur by 
hydrogen bonds, dipole–dipole or π-π interactions have also been used in SPE clean-up of 
vitamin D compounds (29, 30, 95, 101, 113). Some methods used immunosorbents (69) and 
some others used solid-phase microextraction (63). Preparative columns with polar packing 
have also been used as a SPE alternative (52, 96, 97).  
Despite its drawbacks, such as the existence of silanols and lack of stability in a wide range 
of pH, silica-based sorbents have proved to be a very effective strategy for clean-up in 
vitamin D assays. Since many other substances with similar chemical characteristics to 
vitamin D metabolites are present in biological fluids, cross reactivity may easily occur with 
immunosorbent SPEs. Although attractive at the first glance, due to its simplicity, solid-phase 
microextraction lacks robustness owing to the fragile needle. Preparative columns are a good 
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robust alternative to SPE, especially for routine analysis as it is very effective in isolating the 
vitamin and it is reusable therefore qualifies as a green alternative.  
In comparison to LLE, lower volumes and less hazardous solvents are used with SPE and 
there are no emulsion formation problems. Despite its attractive characteristics, SPE is not 
without problems: often the cartridges cannot be used more than once and the procedure is 
time consuming and costly. Moreover, there may be batch-dependent reproducibility issues 
related to SPE cartridges. Although the new trend of automation (online-SPE) increases the 
throughput, it does not necessarily improve the assay in terms of sensitivity. 
 
1.4.1.7 Derivatisation procedures 
Due to the poor ionisation of vitamin D compounds in mass spectrometers, a derivatisation 
procedure based on a Diels–Alder or cycloaddition reaction has been introduced to enhance 
sensitivity in the determination of vitamin D by LC–MS. For the derivatisation of vitamin D 
compounds, a Cookson-type reagent, 4-phenyl-1,2,4-triazoline-3,5-dione (PTAD), has been 
extensively used as dienophile. It directly reacts with the cis-diene structure of vitamin D 
compounds at carbon positions 19, 10, 6 and 5 to produce stable Diels–Alder adducts (115). 
As shown in Table 1, other Cookson-type reagents such as, 4-(4-dimethylaminophenyl)-
1,2,4-triazoline-3,5-dione (DAPTAD) (85-87), 4-(4-diethylaminophenyl)-1,2,4-triazoline-
3,5-dione (DEAPTAD) (85), 4-[2-(6,7-dimethoxy-4-methyl-3,4-dihydroquinoxalinyl-)ethyl]-
1,2,4-triazoline-3,5-dione (DMEQ-TAD) (66), 4-(6-quinolyl)-1,2,4-triazoline-3,5-dione 
(QTAD) (85) and Amplifex (64) have been also used as derivatising reagents; however, they 
are either not commercially available or are significantly more expensive than PTAD. As also 
noted in Table 1, derivatisation is not very common in the LC–MS analysis of vitamin D, 
probably due to the time-consuming nature of the procedure, including several steps. 
However, it is an attractive option for the analysis of minor vitamin D analogues, the 
concentrations of which are too small to be detected by MS of underivatised compounds, and 
for small sized samples such as neonatal biological fluids.  
 
1.4.2 Separation and detection 
Chromatographic techniques are used to separate vitamin D compounds in the extracts from 
other interfering compounds, before detection and quantification. Although GC has also been 
used previously for vitamin D analysis, only LC has performed the separations reported in the 
last years. Most of these LC methods used MS detection and some used UV detection.  
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1.4.2.1 Chromatographic separation 
As shown in table 2, the column type used for chromatographic separation depends largely on 
the form or forms of vitamin D assayed. 
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Table 2. Summary of separation, detection and quantification methods used for the analysis of vitamin D. 
Vitamin D analogues Internal standard Separation conditions Detection Sensitivity (pmol/L)  Refs.  
25(OH)D3, 3-epi-25(OH)D3 25(OH)D4 RP - MeOH:AMM:M (Isocratic) 
 
MS/MS - ESI LOD: 3744 
LOQ: 7488 
 
(83) 
Vitamin D3, Vitamin D2 
25(OH)D3, 25(OH)D2 
1α25(OH)2D2, 1α25(OH)2D3 
3-epi-25(OH)D3, 3-epi-
25(OH)D2 
 
Stanozolol-D3 Chiral-RP - ACN:FA:AmAc (Gradient) MS/MS - ESI LOD: 10 - 50 (58) 
25(OH)D3, 25(OH)D2 
 
25(OH)D3-d3  
 
RP – MeOH:H2O:FA:AmAc (Gradient) MS/MS - ESI LOQ: 5750  
 
(77) 
25(OH)D3, 25(OH)D2, 
3-epi-25(OH)D3  
 
25(OH)D3-d6, 25(OH)D2-d3,  
3-epi-25(OH)D3-d3  
RP – MeOH:H2O:FA:AmAc (Gradient) MS/MS - ESI --------  (62) 
25(OH)D3, 25(OH)D2, 
3-epi-25(OH)D3  
 
25(OH)D3-d3,  
3-epi-25(OH)D3-d3  
PFP – MeOH:H2O:FA (Isocratic) MS/MS - ESI LOD: 500 
LOQ: 2000 
(38) 
D3-S, D2-S, 25(OH)D3-S,  
25(OH)D2-S 
 
D3-S-d3, D2-S-d3, 25(OH)D3-
S-d3, 25(OH)D2-S-d3 
 
RP – MeOH:H2O:AMM (Gradient) MS/MS - ESI LOD: 1.2 – 2.4 
LOQ: 4.2 – 9.2 
(92) 
D3, 25(OH)D3 
 
25(OH)D3-d6, 25(OH)D3-d6  RP – MeOH:H2O:FA:M (Gradient) MS/MS  LOQ: 250* (91) 
25(OH)D3,  
24,25(OH)2D3 
 
 
DAPTAD- d RP – MeOH:H2O:AMM (Gradient) MS/MS - ESI --------  (87) 
D2, D3, 25(OH)D3,  
1,25(OH)2D3 
 
25(OH)D3,  
3-epi-25(OH)D3  
 
D3-d3,  
27-hydroxycholesterol-d6 
 
25(OH)D3-d6 
RP – MeOH:H2O (Gradient) 
 
 
PFP – MeOH:H2O:FA 
MS/MS – APPI 
 
 
MS/MS 
 
LOD: 1250 - 6250 
LOQ: 2500 – 12500 
 
-------- 
(90) 
 
 
(68) 
 
      
25(OH)D3, 25(OH)D2 
 
25(OH)D3-d6 
 
RP - MeOH:AmAc (Isocratic) MS/MS  LOD:  10000 (49) 
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Table 2 (continued). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vitamin D analogues Internal standard Separation conditions Detection Sensitivity (pmol/L)  Refs.  
25(OH)D3, 3-epi-25(OH)D3 25(OH)D2-d3 RP – MeOH:H2O:AMM (Isocratic) MS/MS - ESI -------- (85) 
25(OH)D3, 25(OH)D2 
3-epi-25(OH)D3, 1α(OH)D3 
  
Stanozolol-D3 RP- Chiral - ACN:H2O:FA 
(Gradient) 
MS/MS - ESI LOD: 624 
 
(29) 
25(OH)D3, 25(OH)D2 
24,25(OH)2D3, 3-epi-
25OHD3     
 
25(OH)D3-d6 PFP - MeOH:AmAc (gradient) MS/MS - APCI LOQ: 2000 - 4000 
 
 
(37) 
25(OH)D3, 25(OH)D2 
 
 
25(OH)D3-d3,  
25(OH)D2-d3 
RP - MeOH:H2O:FA:AmAc 
(Gradient) 
MS/MS  LOQ: 6250 
 
 
(73) 
25(OH)D3, 25(OH)D2,  
 
1,25(OH)2D3, 1,25(OH)2D2 
 
25(OH)D3-d6 
 
1,25(OH)2D3-d6 
1,25(OH)2D2-d6 
 
PFP - MeOH:H2O:FA (Isocratic) 
 
RP - MeOH:H2O:FA (Gradient) 
 
MS/MS – APCI 
 
MS/MS  
LOQ: 17500 - 20000  
 
LOD: 4.8 - 72 
(73) 
 
(64) 
24,25(OH)2D3, 25(OH)D3 25(OH)D3-d6 
 
RP - MeOH:H2O:FA (Gradient) MS/MS - ESI LOQ:  250 - 625 (71) 
25(OH)D3, 25(OH)D2,  
3-epi-25(OH)D3 
 
25(OH)D3-d6 
25(OH)D2-d3 
PFP - MeOH:H2O (Isocratic) 
 
MS/MS - APCI LOD: 1880 - 4880 (110) 
25(OH)D3 
 
25(OH)D3-d3 
 
RP - MeOH:AMM 
 
MS/MS - ESI -------- (86) 
25OHD3, 25OHD2 
1,25(OH)2D3, 1,25(OH)2D2 
24,25(OH)2D3 
 
25(OH)D3-d6 
1,25(OH)2D3-d6 
 
RP - MeOH:ACN:H2O:FA 
(Gradient) 
MS/MS - ESI LOQ: 62.4 (36) 
25(OH)D3, 25(OH)D2 
 
25(OH)D3-d6 
25(OH)D2-d6 
RP - MeOH:H2O:AmAc:FA 
(Isocratic) 
MS/MS LOQ:  240 - 780 (74) 
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Table 2 (continued). 
 
Vitamin D analogues Internal standard Analytical conditions Detection method Sensitivity (pmol/L)  Refs. 
D2, D3, 25(OH)D2, 
25(OH)D3,  
24,25(OH)2D3, 
1,25(OH)2D2, 1,25(OH)2D3 
D2-d3, D3-d6, 25(OH)D2-
d3, 25(OH)D3-d6,  
24,25(OH)2D3-d6, 
1,25(OH)2D3-d6 
 
RP – MeOH:H2O:AMM 
(Isocratic) 
MS/MS  LOQ: 37.5 - 375 
 
(72) 
D2, D3, 25(OH)D2, 
25(OH)D3,  
3-epi-25(OH)D3, 
24,25(OH)2D2, 
24,25(OH)2D3, 
1,25(OH)2D2, 1,25(OH)2D3 
 
D2-d3, D3-d3, 25(OH)D2-
d6, 25(OH)D3-d6,  
24,25(OH)2D2-d3, 
24,25(OH)2D3-d6, 
1,25(OH)2D2-d6, 
1,25(OH)2D3-d3 
 
RP – MeOH:H2O:FA 
(Isocratic/Gradient) 
MS/MS - ESI LOD: 0.25 – 0.5 
LOQ: 0.82 – 1.25 
(93) 
25(OH)D3, 3-epi-25(OH)D3  
 
25(OH)D3-d3  
 
RP – ACN:H2O:FA (Gradient) MS/MS - APCI ---------- 
 
 
(70) 
D2, D3, 25(OH)D2, 
25(OH)D3,  
24,25(OH)2D3, 
1,25(OH)2D2, 1,25(OH)2D3 
 
 
D2-d3, D3-d6, 25(OH)D2-
d3, 25(OH)D3-d6,  
24,25(OH)2D3-d6, 
1,25(OH)2D2-d6, 
1,25(OH)2D3-d6 
 
RP – MeOH:H2O:AMM 
(Gradient) 
MS/MS - ESI LOD: 0.75 - 190 
LOQ: 2.5 - 625 
(65) 
D2, D3, 25(OH)D2, 
25(OH)D3,  
 
D3-d6, 25(OH)D2-d6, 
25(OH)D3-d6,  
 
RP – ACN:H2O:M:FA:EtOH 
(gradient) 
MS/MS - ESI LOD: 260 (116) 
25(OH)D3, 24,25(OH)2D3,  
 
 
25(OH)D3-d3,  
24,25(OH)2D3-d6 
Phenyl – MeOH:H2O 
(Gradient) 
MS/MS  --------  (66) 
25(OH)D2, 25(OH)D3,  
 
25(OH)D3-d6  RP – MeOH:H2O:FA 
(Gradient) 
MS/MS - APCI LOQ: 12000 - 12500 
 
(67) 
25(OH)D3, 25(OH)D2 
 
25(OH)D3-d6 
 
RP - RP - 
MeOH:ACN:IPA:ACE:H2O:FA 
(Gradient) 
MS/MS - APCI LOD: 773.76-2132 
LOQ: 2146-3416 
 
(46) 
25(OH)D3, 25(OH)D2 
 
25(OH)D3-d6 
 
RP - MeOH:H2O:AMM 
(Gradient) 
MS/MS - ESI LOD:  3300 (81) 
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Table 2 (continued). 
 
Vitamin D analogues Internal standard Analytical conditions Detection method Sensitivity (pmol/L)  Refs. 
25(OH)D3, 25(OH)D2 
 
25(OH)D3-d6 
 
RP - RP - MeOH:ACN:IPA:ACE:H2O:FA 
(Gradient) 
MS/MS - APCI LOD: 773.76-2132 
LOQ: 2146-3416 
 
(46) 
25(OH)D3, 25(OH)D2 
 
25(OH)D2-d6 
25(OH)D3-d6 
RP - MeOH: AMM (Gradient) 
 
MS/MS – APCI 
MS/MS - ESI 
LOD: 500 – 1000 (APCI) 
LOQ: 1500 - 3000 
LOD: 500 – 1200(ESI) 
LOQ: 1500 – 3600 
 
(79) 
25(OH)D3, 25(OH)D2 
 
25(OH)D3-d6 
 
RP - MeOH:H2O: AmAc:FA (Gradient) MS/MS - ESI LOD: 2500 
LOQ: 4000 - 7500  
 
(56) 
25(OH)D3, 25(OH)D2 
 
25(OH)D3-d6  
25(OH)D2-d6 
 
RP - MeOH:H2O: AmAc:FA (Isocratic) MS/MS - ESI LOQ: 3000 - 4000 (42) 
25(OH)D3, 25(OH)D2 
 
 25OHD3-d6 RP - MeOH:H2O:FA MS/MS - APCI LOQ: 2496 (44) 
Vitamin D3, Vitamin D2 
 
Vitamin D3-d3 
Vitamin D2- d3 
 
RP - MeOH:H2O:AMM (Gradient) MS/MS - APCI LOD: 1559* 
LOQ: 4367* 
(99) 
Vitamin D3, Vitamin D2 
 
Vitamin D3-d3 
 
RP - MeOH:H2O:FA (Gradient) MS/MS - APCI LOD: 1689-2092* 
LOQ: 5719-7059* 
 
(97) 
1α 25(OH)2D3 
 
1α 25(OH)2D3-d6 
 
RP - MeOH:LiAc (Gradient) 
 
MS/MS - ESI LOD: 7.2 
LOQ: 36 
 
(39) 
25(OH)D3, 25(OH)D2 
 
25(OH)D3-d6,  
25(OH)D2-d6 
 
RP - MeOH:H2O (Isocratic) MS/MS - APCI LOD: 1700-1200 
LOQ: 4600-3000 
 
(50) 
25(OH)D3, 25(OH)D2 
 
25(OH)D3-d6 
 
PFP - MeOH: AmAc:FA MS/MS - ESI ------- (84) 
25(OH)D3, 25(OH)D2 
 
25(OH)D3-d3 
25(OH)D2-d3 
CN - MeOH:H2O (Isocratic) MS/MS - APCI LOD: 374* (61) 
 
25(OH)D3 
 
 
25(OH)D4 
 
RP  - RP - MeOH:AMM:M (Isocratic) 
 
MS/MS - ESI 
 
LOD:  4.99 
 
(88) 
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Table 2 (continued). 
 
 
Vitamin D analogues Internal standard Analytical conditions Detection method Sensitivity (pmol/L)  Refs. 
Vitamin D3 
 
Vitamin D3-d6 
 
RP - MeOH:AmAc (Isocratic)  MS/MS - APCI LOQ: 1299 - 12999 
 
(63) 
Vitamin D3, Vitamin D2 
 
Vitamin D3-d3 
Vitamin D2-d3 
RP - MeOH:AMM (Gradient) MS/MS - APCI LOD: 5042-12219* 
LOQ: 15378-37437* 
(95) 
25(OH)D3-S 25(OH)D3S-d3 RP – MeOH:H2O:AMM (Gradient) MS/MS - ESI LOQ: 5210 (21) 
      
25(OH)D3, 25(OH)D2 
24,25(OH)2D3, 1,25(OH)2D3 
1,25(OH)2D2  
 
25OHD3-d6 
25(OH)D2-d6 
1,25(OH)2D3-d6 
1,25(OH)2D2-d6 
 
RP - MeOH:H2O:FA:M (Gradient) MS/MS - ESI LOQ: 24.96 - 48 
 
(75) 
25(OH)D3, 25(OH)D2 
1α 25(OH)2D3 
24,25(OH)2D3 
 
25OHD2-d6,  
25(OH)D3-d6 
1α25(OH)D3-d6 
 
RP - MeOH:AMM (Gradient) MS/MS - ESI LOD: 1.24 – 2.4 
LOQ: 12 – 249 
(43) 
1α25(OH)2D3, 1α25(OH)2D2 
 
1α25(OH)2D3-d6 
1α25(OH)2D2-d6 
RP – (No details)  MS/MS - ESI LOD: 1.5 
LOQ: 3.0 
 
(69) 
1α25(OH)2D3, 1α25(OH)2D2 
 
1α25(OH)2D3-d6 
1α25(OH)2D2-d6 
RP - MeOH:H2O:LiAc (Gradient) MS/MS - ESI LOQ: 8.16 - 9.09 (immunotube) 
LOQ: 37.92 – 32.42 (IDS antibody) 
  
(47) 
Vitamin D3 
 
Vitamin D3-d6 RP - MeOH:H2O:AMM (Gradient) MS/MS - ESI LOD: 208 
LOQ: 363 
 
(100) 
25(OH)D3, 25(OH)D2 
 
25(OH)D3-d6, 
25(OH)D3-d6 
 
RP - MeOH:H2O (Gradient)  MS/MS - APPI LOQ: 1300 (45) 
25(OH)D3, 1α25(OH)2D3 
24,25(OH)2D3,  4β25(OH)D3  
25(OH)D3-d6 
1α25(OH)2D3-d6  
RP - ACN:H2O:FA (Gradient) MS/MS - ESI LOD: 2.4 - 9.98 
LOQ: 60 - 124 
(80) 
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Table 2 (continued). 
 
Vitamin D analogues Internal standard Analytical conditions Detection method Sensitivity (pmol/L) Refs.  
Vitamin D3 
 
Vitamin D3-d6 RP-RP - MeOH:ACN:FA (Gradient) MS/MS - ESI LOD: 1299 – 2079* (food) 
 33.79** (Pharmaceuticals) 
LOQ: 2599 – 4159* (food) 
 5199** (Pharmaceuticals) 
 
(114) 
25(OH)D3, 25(OH)D2 
 
25(OH)D3-d6, 25(OH)D2-d6 CN-RP – MeOH:H2O:FA (Gradient) MS/MS - APCI LOD: 1260 
LOQ: 2496 
(48) 
25(OH)D3, 25(OH)D2 
 
25(OH)D3-d6 RP - EtOH:H2O (isocratic) MS/MS - APCI LOD: 1223-4507 (40) 
Vitamin D3 
 
Vitamin D3-d3 
 
PFP - MeOH:ACN:H2O:FA (Gradient) MS/MS - APCI LOD: 5199-20798* (30) 
Vitamin D2, Vitamin D3 
25(OH)D3, 25(OH)D2 
 
Vitamin D2-d6 
Vitamin D3-d6 
25(OH)D3-d6   
25(OH)D2-d3 
 
RP - MEOH:H2O:T (Gradient) MS/MS - APPI LOQ: 2521-4846 (57) 
1,25(OH)2D2 
  
1α,24(OH)D2-d8 
 
RP -  ACN:H2O (Gradient) 
 
MS/MS - APCI 
 
LOQ: 58.32  (41) 
25(OH)D3, 25(OH)D2 
 
25(OH)D3-d6 RP – MeOH:AmAc:FA (Gradient) MS/MS - ESI LOD: 1200-1500 
LOQ: 3500-2000 
(59) 
25(OH)D3 
 
25(OH)D3-d6 RP -  MeOH:H2O:FA (Gradient) MS - APCI LOD: 4992 – 12480* (89) 
25(OH)D3, 25(OH)D2 
3-epi-25(OH)D3 
 
25(OH)D3-d6   
25(OH)D2-d3 
1. RP -  MeOH:H2O (Gradient)  
2. CN - MeOH:H2O (Isocratic)  
3. PFP - MeOH:H2O (Isocratic) 
4.  
MS - APCI LOD: 2496 – 4992* 
LOQ: 7488 – 14976* 
(60) 
Vitamin D3 
 
Vitamin D3-d3  RP - MeOH:ACN:H2O (Gradient) 
5.  
MS/M - APCI 
MS - APCI  
 
------- (101) 
Vitamin D3 Vitamin D3-d3 
 
6. RP - MeOH:H2O:AMM (Isocratic) 
7. RP - MeOH:H2O (Isocratic) 
MS/MS – ESI         
MS
n
 - APCI 
LOQ: 260 - 520 (33) 
  8.     
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Table 2 (continued). 
 
 
  
Vitamin D analogues Internal standard Analytical conditions Detection method Sensitivity (pmol/L) Refs.  
25(OH)D3, 25(OH)D2 ------- RP - MeOH:H2O (Isocratic) DAD – 265 nm LOD: 6000 - 12000 
LOQ: 4000 
 
(52) 
Vitamin D3  
 
Vitamin D2 RP - MeOH:ACN (Isocratic) DAD – 265nm LOD: 64995 (103) 
Vitamin D3 ------- RP - SDS:BuOH:PB (Isocratic)  DAD – 230, 280, 300 nm LOD: 2365848 
LOQ: 7097545 
 
(112) 
Vitamin D3, Vitamin D2 
25(OH)D3, 25(OH)D2 
 
1α(OH)D3 RP - MeOH:EtOH (Gradient) UV – 265 nm ------- (82) 
25(OH)D ------- RP - ACN:MeOH:IPA (Gradient) UV – 268 nm 
 
LOD: 8000 
 
(53) 
Vitamin D3 ------- RP - MeOH:ACN (Isocratic) UV – 285 nm LOD: 12999  
LOQ: 117187 
 
(55) 
25(OH)D3 
 
Retinyl acetate RP - MeOH:H2O (Isocratic) UV – 265 nm LOD: 10000  (76) 
25(OH)D3, 25(OH)D2 
3-epi-25(OH)D3 
 
Laurophenone CN - MeOH:H2O (Isocratic) 
CN -  MeOH:H2O:FA (Isocratic) 
MS/MS - APCI 
UV – 275 nm 
LOD: 249.60 (28) 
Vitamin D3, 25(OH)D3 
 
Vitamin D2 
 25(OH)D2 
RP - MeOH-H2O-HAc (Isocratic) 
RP - MeOH:H2O (Isocratic) 
 
MS/MS – APCI 
UV-DAD – 265, 280 nm  
 
LOD: 998-1039* (96) 
Vitamin D3  
 
Vitamin D2 RP - MeOH:MeOH (Isocratic) MS - APCI 
UV – 265 nm 
 
------- (82) 
Vitamin D3 
 
 Vitamin D2 RP-RP - MeOH:ACN:DCM (Gradient)  MS – APCI 
UV – 265 nm 
1. LOD: 17938 - 188747 
2. LOQ: 59536 - 629159 
3.  
(102) 
25(OH)D3 ------- Anti-25(OH)D3 ELISA -Visible-450nm LOD: 5500 (54) 
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Table 2 (continued). 
 
Vitamin D analogues Internal standard Analytical conditions Detection method Sensitivity (pmol/L) Refs.  
25(OH)D ------- Anti-25(OH)D   RIA - Radioimmunoassay  
CLIA - Chemiluminescence  
ECLIA – Electrochemiluminescence 
 
------- (51) 
25(OH)D ------- Anti-25(OH)D RIA - Radioimmunoassay 
CLIA – Chemiluminescence 
 
------- (78) 
1α25(OH)2D3 
 
------- Anti-1,25(OH)2D3 SERS 
 
LOD: 4.32 (117) 
Vitamin D3 ------- Silica gel plates, C:E HPTLC ------- (98) 
*Expressed in pmol/kg , **Expressed in pmol/tablet  
Abbreviations:ACE, acetone; ACN, acetonitrile; AmAc, ammonium acetate; AMM, ammonium formate; APPI, atmospheric pressure 
photoionisation; APCI, atmospheric pressure chemical ionisation; BB, borate buffer; BuOH, butanol; C, chloroform; CN, cyanopropyl column; 
DAD, diode array detector; DCM, dichloromethane; E, ether; ESI, electrospray ionisation; FA, formic acid; HAc, acetic acid; H2O, water; 
LiAc, lithium acetate; LOD, limit of detection; LOQ, limit of quantitation; M, methylamine; MeOH, methanol; PB, phosphate buffer; PBS, 
phosphate buffer saline; RP, reverse phase; PFP, pentafluorophenyl column; SDS, sodium dodecyl sulphate; SERS, surface-enhanced Raman 
scattering; T, toluene.    
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As shown in table 2, D2 and/or D3 were separated and detected in foodstuffs (30, 94-99, 111-
114). The majority of the methods for serum/plasma separated and detected 25(OH)D2 and 
25(OH)D3, while others assayed only 25(OH)D3. Some methods separated epimers (28, 29, 
37, 58, 60, 83, 110). A few others have separated and detected many forms of vitamin D 
compounds (36, 43, 57, 75, 80, 82). Due to the hydrophobic characteristics of vitamin D 
compounds and the derivatives, reversed-phase (RP) was the most commonly used LC 
column type. A relatively uncommonly used method, HPTLC, has also been developed to 
determine D3 in fish oil (98).  
Even though LC–MS/MS provides outstanding specificity, a challenge encountered in 
vitamin D assay is the separation of epimers. The epimeric form and the corresponding 
vitamin analogues have the same mass and same fragmentation patterns hence, they cannot 
be differentiated by LC–MS/MS. This imposes a high demand on the separation step to 
prevent co-elution of the epimers. PTAD derivatisation has been employed to enhance the 
MS response of 25(OH)D3; thus, 25(OH)D3 has been separated from its epimer by using a RP 
column after PTAD-derivatisation (70, 83, 93). Other methods have not used any 
derivatisation procedure and the separation of 25(OH)D3 from its epimer has been achieved 
using either a cyano column (28, 60); a RP column in tandem with a chiral column (29, 58); 
or a pentafluorophenyl column (37, 38, 60, 68, 110). Four analogues excluding epimers were 
separated using a RP column (57, 82). Four (43, 80) or five (36, 75) analogues excluding 
epimers were separated using PTDA-derivatisation and a RP column. Four analogues 
including epimers were separated using a pentafluorophenyl column or RP in tandem with a 
chiral column (29, 37). Eight analogues were separated using RP in tandem with a chiral 
column (58).  
 
1.4.2.2 Detection 
As shown in table 2, MS has been an increasingly popular detection method for the analysis 
of vitamin D compounds due to its high specificity and sensitivity. Although few studies (45, 
57, 90) have used ionisation sources such as atmospheric pressure photoionisation, ESI and 
atmospheric pressure chemical ionisation modes remain the most frequently used and the 
majority of methods used LC–MS/MS rather than LC–MS. The major weakness of MS in 
vitamin D analysis is the low ionisation ability of vitamin D compounds, and in some cases 
this problem has been overcome by derivatisation, as discussed in the section titled 
‘Derivatisation procedures’. Although UV detection has been largely replaced by MS 
detection due to its poor specificity and/or sensitivity, it is still used as a less expensive 
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detection option, as shown in table 2. Based on the chemical structure/chromophore of 
vitamin D analogues, these compounds absorb at approximately 265 nm. NMR spectrometry 
has also been assessed to detect four vitamin D analogues (118).  
As shown in table 2, there are many different immunoassay kits commercially available for 
vitamin D assay. With immunoassays, after the initial sample preparation/clean-up step the 
extract is subjected to an antibody specific vitamin D assay. The detection step of 
immunoassays is based on different spectroscopic techniques such as UV-visible (54), 
chemiluminescence (51, 78), Raman scattering (117) or radioactivity measurements (51, 78). 
Two major limitations of immunoassays for vitamin D analysis are matrix effects and the 
inability to distinguish between 25(OH)D3 and 25(OH)D2 (8). Raman (117) spectroscopy for 
immunoassay has shown high sensitivity, enabling the detection of vitamin D metabolites at 
very low concentrations; however, this method still cannot distinguish between the different 
vitamin D metabolites. 
 
1.4.2.3 Quantification 
Despite its strong advantages over other analytical techniques, one of the major drawbacks of 
MS detection is its susceptibility to matrix effects. Matrix effects in MS occur when the 
compounds that co-elute with the analyte interfere with the ionisation process causing 
ionisation suppression or enhancement. As there is no way to ensure complete elimination of 
the interfering compounds that co-elute with the analyte, the only way to obtain accurate data 
is to remove the contribution from the interferences at the quantification step. The inclusion 
of stable isotope labelled (SIL) internal standard (IS) in the sample and subsequent 
quantification using IS calibration has become the most commonly used method to correct for 
matrix effects in MS detection (119). As the chemical properties and ionisation process of 
SIL IS are almost identical to those of the analyte, and as it elutes at the same retention time 
as the analyte and experiences the same extent of matrix effects, it provides the best option to 
use in IS calibration methods with LC–MS.  
As shown in table 2, some MS methods did not employ SIL IS and, therefore, matrix effects 
were not specifically removed as a result (28, 29, 58, 83, 88). Most methods used SIL IS such 
as d6-25OHD3 (36, 37, 40, 42-46, 48-50, 56, 59, 65, 67, 68, 71, 72, 74, 75, 79-81, 84, 89, 91, 
110), d6-25OHD2 (42, 43, 45, 48, 50, 57, 75, 79), d6-1,25(OH)2D3 (36, 39, 43, 47, 65, 69, 72, 
75, 80) and d6-1,25(OH)2D2 (47, 65, 69, 75) for the correction of matrix effects at the 
quantification step. Some methods used a single SIL IS for all vitamin forms (37, 40, 44, 46, 
49, 56, 59, 81, 97) although this does not remove matrix effects from all vitamin D analytes 
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except the form that co-elutes with the IS (119). Quantification in LC-UV methods has used 
either IS calibration using non co-eluting compounds such as vitamin D2 (94, 96, 102, 103), 
25(OH)D2 (96), 1α(OH)D3 (82), laurophenone (28), retinyl acetate (76) or external standard 
calibration.  
All LOD and LOQ values in Table 2 were presented in the same units (pmol/L or pmol/Kg) 
so that a comparison of sensitivities was possible. According to Tables 1 and 2, in general, 
PTAD derivatisation increased the sensitivity although in some cases it was not high relative 
to other methods (53, 59, 61). Interestingly, some LC–MS/MS methods with no derivatisation 
(39, 41, 47, 58) and an immunoassay reported very high sensitivities (117). 
 
1.5 Conclusion 
This chapter summarises the most used vitamin D methods for all applications. Particular 
emphasis has been placed on the different forms of vitamin D measured and the sample 
preparation procedures used in a variety of matrices. This chapter was divided into sections 
based on the typical steps of an analytical method, and the vitamin D methods were compared 
and critically evaluated at each step. This enabled the evaluation of each stage of the 
analytical process and selection or development of an appropriate method for a specific 
application. In general, saponification was the method of choice to extract the vitamin from 
food stuff while PP was used with plasma and serum. DBS has been a popular sample 
collection method for small sample volumes, although a recent study (106) found that this 
method introduces high variability to the assay. Overall, LC–MS/MS is the most common 
technique used and it is the best option for the unambiguous identification and accurate 
quantification of the many different forms of vitamin D. 
Vitamins D2 and D3 are the forms commonly measured in food. Other native forms were 
disregarded due to the relatively low levels compared with the often fortified vitamin levels. 
Although controversy exists regarding the inadequacy of the choice, the form 25(OH)D 
continues to serve as the marker for vitamin D in plasma and serum (120). However, 
widespread variation in measurement results for 25(OH)D warranted the establishment of 
reference measurement procedures and standardisation efforts (121, 122). As evident from 
the content of this review, assays for forms other than 25(OH)D in plasma and serum are not 
common, therefore standardisation of methods for these forms is not likely to occur in the 
near future. The development of new LC–MS/MS sources as well as improvements on 
derivatisation procedures are expected to address issues related to the poor ionisation 
efficiency in ESI or atmospheric pressure chemical ionisation of vitamin D compounds. 
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Advances in automation of sample preparation techniques are in progress and will continue 
due to the demand for high throughput and greener technologies. 
 
1.6 Research hypothesis 
1. The quantification of all individual major forms (twelve rather than four commonly 
measured) of vitamin D in biological fluids will provide an accurate estimation of the 
total vitamin D status.  
2. The pasteurisation process will affect the concentration of vitamin D in breastmilk.  
 
1.7 Research aims 
1. To develop an accurate and sensitive LC-MS/MS method for the quantification of 
twelve major forms of vitamin D in milk by optimisation of each step of the analytical 
method: extraction, sample preparation, separation and detection. 
2. To validate the developed method. 
3. To apply the method to quantify the total vitamin D in milk from several species. 
4. To apply the method to evaluate the effect of pasteurisation on the vitamin D content 
in breastmilk. 
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2 Chapter 2: Development and validation of a method for the quantitative analysis 
of eight vitamin D analogues in milk using liquid chromatography-tandem mass 
spectrometry 
 
2.1 Foreword 
This chapter describes the attempts to develop and validate an LC-MS/MS method for the 
sensitive and accurate quantification of vitamin D compounds in milk. It explores in detail 
the strategies used to improve the ionisation efficiency of vitamin D compounds, to achieve 
an efficient extraction method and to produce adequate chromatography. The majority of the 
content of this chapter has been published in the journal Analytica Chimica Acta, 3; 891:211-
20 (2015) and it is presented in a slightly modified format to fit with the style of this thesis. 
Permission has been granted from the publisher to reproduce the work in the thesis. 
 
2.2 Introduction 
Vitamin D is essential in the regulation of the intestinal absorption of calcium and phosphate, 
both of which are vital for healthy homeostasis of bones. Osteomalacia in adults and rickets 
in infants are the most common adverse effects related to an insufficiency of vitamin D (13). 
Vitamin D deficiency has also been associated with many non-skeletal disorders such as 
common cancers, hypertension, cardiovascular disease, diabetes mellitus and autoimmune 
diseases (4). There has been an increase in the interest in vitamin D status because of its 
implications on these major diseases (123).  
Each vitamin D form has a different function in the body (13, 21, 27). Most biological actions 
of vitamin D are attributed to the metabolite 1,25-dihydroxyvitamin D (1,25(OH)2D3 and 
1,25(OH)2D2) that is primarily responsible for preventing skeletal and non-skeletal disorders 
mentioned earlier. The metabolite 24,25-dihydroxyvitamin D (24,25(OH)2D3 and 
24,25(OH)2D2) was originally considered to be inactive but was later found to play a crucial 
role in intramembranous and endochondral bone formation and in bone fracture repair (13). It 
has also been suggested that vitamin D3 (D3) is more efficiently absorbed by the intestine 
than vitamin D2 (D2) (124, 125). The metabolite 25-hydroxyvitamin D3 (25(OH)D3) has three 
times the potency (126) and higher affinity than 25-hydroxyvitamin D2 (25(OH)D2) to 
vitamin D-binding protein (DBP), which results in a higher biological half-life (124). 
25(OH)D3 can be epimerised to an inactive form (3-epi-25(OH)D3) and collective 
measurement of these two isomers can lead to an overestimation of the vitamin D content 
(27, 123). Given the diverse and varying activities and biological functions of different 
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analogues of vitamin D, it is desirable to simultaneously measure all key vitamin D analogues 
using an analytical method with high specificity and sensitivity (120). The attempts to 
develop and validate an LC-MS/MS method for the sensitive and accurate quantification of 
twelve vitamin D forms in milk are described in this chapter.  
Numerous vitamin D assays in biological fluids have been reported based on different 
techniques (123); however, few have been developed for application to milk samples and 
even fewer for unfortified milk. Immunoassay methods such as competitive protein binding 
assays (CPBA) have been applied for the determination of vitamin D in unfortified milk (127, 
128). The main drawback of immunoassay methods is their inability to distinguish between 
different forms of vitamin D (123). Liquid chromatography (LC) methods have also been 
used for the analysis of vitamin D compounds in milk, and they have the advantage over 
immunoassays because of their ability to differentiate a variety of vitamin D compounds in a 
single run. Electrochemical (EC) (129) and ultraviolet (UV) (130, 131) detectors have been 
the detectors of choice until recently. Recently, tandem mass spectrometry (MS/MS) 
detection has been gaining popularity due to its superior sensitivity and specificity. 
Nevertheless, poor ionisation efficiency in the atmospheric pressure ionisation (API) of 
vitamin D compounds has been a drawback (123). In order to address this critical factor, a 
derivatisation procedure based on the Diels-Alder reaction has been introduced to enhance 
the ionisation efficiency and thereby the sensitivity of vitamin D assay (132). Derivatisation 
with 4-phenyl-1,2,4-triazoline-3,5-dione (PTAD) has proved to be an effective strategy for 
the analysis of minor vitamin D compounds, the concentrations of which are too small to be 
detected by standard MS methods and also for small volume samples such as neonatal 
biological fluids (83, 104). The PTAD derivatisation method was initially optimised for the 
analogues D3, lα(OH)D3, 25(OH)D3, l,25(OH)2D3 and 24,25(OH)2D3, as a post-column 
derivatisation method to use prior to thermospray mass spectrometry detection. It was found 
to increase the sensitivity between 7 and 70-fold, depending on the vitamin D compound 
(133). This method has subsequently been used as a pre-column derivatisation method for 
many vitamin D analogues, but without rigorous optimisation. In this study, we have 
optimised the pre-column derivatisation step and compared the sensitivities of derivatised and 
underivatised forms of four major forms (and one minor form) of vitamin D in biological 
fluids. 
Vitamin D compounds in b iological fluids or foods are bound to proteins and lipids and 
therefore are required to be released before analysis. Two approaches have been commonly 
used for this process: protein precipitation and saponification. Traditionally, saponification 
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was used for foodstuffs while protein precipitation has largely been used for plasma/serum, 
with the exception of two studies that used saponification for plasma/serum (123). In this 
study, we compared the performances of the two approaches, saponification and protein 
precipitation, for their effectiveness in releasing the vitamin from milk. Also, the method 
reported here can resolve 25(OH)D3 and its inactive epimeric form and thereby prevent an 
overestimation of vitamin D concentration in milk samples. To correct for the ionisation 
suppression or enhancement effects and thereby ensure the highest accuracy and reliability of 
our LC-MS/MS method (134) we included a co-eluting stable isotope labelled internal 
standard for each analogue of vitamin D quantified. Since the more widespread availability of 
MS detection, quantitative methods have been developed for the determination of D2, D3, 
25(OH)D2 and 25(OH)D3 analogues in milk (135). The developments and optimisation 
procedures outlined in this study have been used to expand the scope to include eight 
additional vitamin D analogues, 1,25(OH)2D2, 1,25(OH)2D3, 24,25(OH)2D2, 24,25(OH)2D3, 
vitamin D2-Sulfate (D2-S), vitamin D2-Sulfate (D3-S), 25-hydroxyvitamin D2-Sulfate 
(25(OH)D2-S) and 25-hydroxyvitamin D3-Sulfate (25(OH)D3-S). In addition, the pre-vitamin 
7-dehydrocholesterol (7-DHC) was also included in a standard mixture and ensured 
chromatographic separation from isobaric D3. The method developed has been validated and 
subsequently used to quantify and compare the total vitamin D profiles of several different 
types of milk: human, cow, mare, goat and sheep. 
 
2.3 Material and methods 
2.3.1 Chemicals and samples 
The following unlabelled and deuterium-labelled (d3 or d6) standards: D2, D3, 25(OH)D2, 
25(OH)D3, 3-epi-25(OH)D3, 24,25(OH)2D2, 24,25(OH)2D3, 1,25(OH)2D2, 1,25(OH)2D3, D2-
S, D3-S, 25(OH)D2-S, 25(OH)D3-S, D2-d3, D3-d3, 24,25(OH)2D3-d6, 1,25(OH)2D3-d3, D2-S-
d3, D3-S-d3, 25(OH)D2-S-d3 and 25(OH)D3-S-d3 were purchased from IsoSciences (King of 
Prussia, USA). Other labelled standards were purchased from Chemaphor (Ottawa, Canada) 
(25(OH)D2-d6 and 25(OH)D3-d6), Medical Isotopes Inc. (Pelham, USA) (1,25(OH)2D2-d6), 
and Toronto Research Chemicals Inc. (Ontario, Canada) (24,25(OH)2D2-d3). All compounds 
had a purity of 97% or better. PTAD (≥97%) was purchased from Sigma Aldrich (St. Louis, 
USA). Organic solvents of LC-grade (dichloromethane, hexane, acetonitrile and methanol), 
and chemicals of analytical grade (potassium hydroxide (KOH), ascorbic acid (Asc) and 
ethanol (EtOH) were purchased from Merck (Darmstadt, Germany)). LC-MS grade formic 
acid (>99%) was purchased from Fisher Chemical (Geel, Belgium). High-purity water was 
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prepared by using a Millipore Milli-Q system (Milford, USA). Human milk samples were 
kindly donated by the breast milk bank of the Royal Brisbane and Women's Hospital 
(RBWH), Brisbane, Australia. Cow, mare, goat and sheep milks were kindly donated by Dr 
John Wright, School of Veterinary Science, The University of Queensland (UQ). 
 
2.3.2 LC-MS/MS analysis 
Chromatographic separations were carried out using an Agilent binary LC system consisting 
of an Agilent 1290 infinity LC pump, an Agilent 1290 well plate auto-sampler and a 
Poroshell 120 EC-C18 (150 x 2.1 mm, 2.7 µm) column (Agilent Technologies, Santa Clara, 
CA, USA). For experiments using non-derivatised vitamin D, the separations were carried 
out using a Pursuit PFP (150 x 3.0 mm, 3 µm) column (Agilent Technologies, Santa Clara, 
CA, USA). An Agilent 6460 Triple Quadrupole tandem mass spectrometer equipped with a 
Jet Stream and supported by Mass Hunter Workstation software (Agilent Technologies, Santa 
Clara, CA, USA) was used as the detector. A binary solvent system consisting of 0.1% 
formic acid in water (A) and 0.1% formic acid in methanol (B) was used for separation. 
Isocratic elution was used for the first 12.5 min (77% B), the composition changed to 100% B 
over the next 1.5 min, and remained at 100% B for the next 9 min. The composition returned 
to 77% B during the next 1 min, and the column was then re-equilibrated with 77% B for 10 
min before injecting the next sample. The flow rate was 0.2 mL/min
-1
 and the injection 
volume was 20 µL. Mass spectrometry parameters such as fragmentor and collision energies 
were optimised to obtain the highest possible sensitivity for each compound, as shown in 
Table 3. 
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Table 3. Optimised mass spectrometry parameters used in MRM mode for all vitamin D. 
 
 
Table 3 also shows the m/z of precursor, product and qualifier ions used in MRM mode for 
each vitamin D compound. Source parameters such as gas flow, sheath gas flow, gas 
temperature and sheath gas temperature were optimised and maintained at 5 L/min, 12 L/min, 
300 
o
C and 250 
o
C respectively. The capillary and nozzle voltages were maintained at 5000 
and 2000 V respectively. The non-derivatised forms of 25(OH)D2, 25(OH)D3 and                   
3-epi-25(OH)D3 analogues were analysed according to a published study (38). This method 
was further adapted to accommodate the compounds D2 and D3. Briefly, a binary solvent 
system consisting of 0.1% formic acid in water (A) and 0.1% formic acid in methanol (B) 
was used for separation. An isocratic elution was used for the first 12 min (80%, B), the 
composition changed to 100% B over the next 10 min, and maintained at 100% B for the next 
2 min. The composition returned to 80% B during the next 1 min, and the column was then 
re-equilibrated with 80% B for 10 min before injecting the next sample. The flow rate was 
Compound Precursor 
ion (m/z) 
Product 
ion (m/z) 
Qualifier 
ion (m/z) 
Fragmentor 
(V) 
Collision 
energy (V) 
D2 572 298 161 96 16 
D2-d3 575 301 ---- 96 16 
D3 560 298 161 96 12 
D3-d3 563 301 ---- 96 12 
25(OH)D2 570 298 161 144 12 
25(OH)D2-d6 576 298 ---- 144 12 
25(OH)D3 558 298 161 168 12 
25(OH)D3-d6 564 298 ---- 168 12 
1,25(OH)2D2 586 314 135 144 12 
1,25(OH)2D2-d6 592 314 ---- 144 12 
1,25(OH)2D3 574 314 177 139 8 
1,25(OH)2D3-d3 577 317 ---- 139 8 
24,25(OH)2D2 586 298 161 178 12 
24,25(OH)2D2-d3 589 298 ---- 178 12 
24,25(OH)2D3 574 298 161 198 20 
24,25(OH)2D3-d6 580 298 ---- 198 20 
D2-S-PTAD  652 378 161 134 16 
D2-S-d3-PTAD  655 381 ----- 134 16 
D3-S-PTAD  640 378 161 124 12 
D3-S-d3-PTAD  643 381 ----- 124 12 
25(OH)D2-S-PTAD  650  378 161 144 12 
25(OH)D2-S-d3-PTAD  653  381 ----- 144 12 
25(OH)D3-S-PTAD  639 378 161 144 12 
25(OH)D3-S-d3-PTAD  642 381 ----- 144 12 
7-DHC 560 365 157 134 24 
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0.2 mL min
-1
 and the injection volume was 20 uL. The mass spectrometer was operated in 
ESI positive mode. The detection was performed in MRM mode as follows: D2, m/z 397-83; 
D3, m/z 385-159; 25(OH)D2, m/z 413-83 and 25(OH)D3 and 3-epi-25(OH)D3, m/z 401-159. 
The fragmentor and collision energy voltages were maintained at 96 and 24 V, respectively. 
Source parameters such as gas flow, sheath gas flow, gas temperature and sheath gas 
temperature were maintained at 5 L/min, 12 L/min, 300
o
C and 250
o
C respectively. The 
capillary and nozzle voltages were maintained at 5000 V and 2000 V, respectively. 
 
2.3.3 Preparation of standard and sample solutions 
All sample and standard preparations were carried out under subdued light. All standard 
compounds were dissolved in ethanol to obtain 10 nM stock solutions that were stored at -20
o
 
C. Working solutions were prepared by serial dilutions from the stock solutions. Each milk 
sample was vortex mixed and 4 mL aliquots were accurately measured and frozen until 
extraction and analysis.  
 
2.3.4 Optimization of derivatisation reaction with PTAD 
The derivatisation reactions between PTAD and five vitamin D analogues, D2, D3, 25(OH)D2, 
25(OH)D3 and 3-epi-25(OH)D3, were optimised: the molar ratios of PTAD:vitamin were 
varied from 5 to 30,000; the time of reaction was varied from 1 to 16 h. All procedures were 
carried out under subdued light. Briefly, a stock solution of PTAD was prepared in 
acetonitrile at a concentration of 800 µM and working solutions were prepared by serial 
acetonitrile dilutions from the stock solution. The mixed standard solution (10 µL) was dried 
down under a gentle stream of nitrogen and then 100 µL of PTAD solution (0.025, 0.5, 5, 50 
or 150 µM) was added to give a molar excess of 5, 100, 1000, 10,000 or 30,000-fold 
respectively, and the solutions vortex mixed for 1 min. These solutions were allowed to react 
at room temperature for 1, 5 or 16 h, after which time 50 µL of ethanol was added to stop the 
reaction. The solutions were dried down under a gentle stream of nitrogen and the residues 
reconstituted with 100 µL mobile phase (77% B composition). These solutions were 
centrifuged for 5 min at 4000 g before using the supernatant for LC-MS/MS analysis. The 
underivatised forms of the same analogues were prepared in mobile phase at the same final 
concentration (1 nM) and both derivatised and underivatised forms were analysed using 
separate LC-MS/MS procedures, as described above. Peak height ratios (signal/noise) were 
used to compare the effect of derivatisation. 
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2.3.5 Optimisation of sample preparation 
2.3.5.1 Protein precipitation (PP) 
Eight millilitres of acetonitrile was added to 4 mL milk and vortex mixed for 2 min. The 
samples were incubated at room temperature for 15 min to complete the protein precipitation, 
and then centrifuged for 10 min at 4000 g. The supernatant was transferred to a fresh 
centrifuge tube and subjected to further liquid-liquid extraction (LLE), as described below. 
 
2.3.5.2 Saponification (SN) 
Four millilitres of 8 M ethanolic KOH solution and 2.8 mL of 1 M of ascorbic acid (Asc) 
were added to 4 mL milk. The mixture was vortex mixed for 2 min and incubated at room 
temperature for 12 h, followed by centrifugation for 10 min at 4000 g. The supernatant was 
transferred to a fresh centrifuge tube and subjected to further liquid-liquid extraction (LLE), 
as described below. 
 
2.3.5.3 Liquid-liquid extraction (LLE) 
Twelve millilitres of hexane:dichloromethane (4:1, v/v) mixture were added to the solution 
prepared in PP or SN above, and vortex mixed for 2 min. The upper organic layer was 
transferred to a centrifuge tube and the process repeated for a second time. The two batches 
of supernatants were pooled and evaporated to complete dryness under a gentle stream of 
nitrogen at room temperature. 
 
2.3.5.4 Derivatisation procedure 
The residue obtained from LLE (for standards and samples) was derivatised with PTAD 
using the optimum conditions (10,000-fold excess of PTAD with one-hour reaction time) and 
reconstituted with mobile phase as described above. 
 
2.3.5.5 Method validation 
Linearity was estimated by using six mixed standard solutions, derivatised and then dissolved 
in mobile phase, containing 0.05-5.0 nM (D2, D3, 25(OH)D3 and 24,25(OH)2D3), 0.05-0.5 
nM (D2-S, D3-S, 25(OH)D2-S, 1,25(OH)2D2, and 1,25(OH)2D3), 0.05-1 nM (25(OH)D3-S, 
25(OH)D2, and 24,25(OH)2D2), 1 nM (D2-d3, D3-d3, 25(OH)D3-d6 and 24,25(OH)2D3-d6), 0.2 
nM (D2-S-d3, D3-S-d3, 25(OH)D2-S-d3, 25(OH)D3-S-d3, 1,25(OH)2D2-d6, and 1,25(OH)2D3-
d3) and 0.2 nM (25(OH)D2-d6 and 24,25(OH)2D2-d3). The linearity was assessed by plotting 
the peak area ratios of each unlabelled form and its respective labelled form versus the 
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concentration of unlabelled standard. The limits of detection (LOD) and limits of quantitation 
(LOQ) for each compound were determined based on the concentrations (based on peak 
heights) corresponding to 3x noise and 10x noise respectively. Repeatability was estimated 
by analysing 10 individual aliquots of a human milk sample followed by the calculation of 
relative standard deviation of the concentrations determined for each vitamin compound. 
Recovery was determined by using the concentrations of each vitamin D analogue 
determined for six aliquots each of spiked and unspiked human milk samples. Each aliquot of 
milk was spiked to give an added concentration similar to the mid-point of the calibration 
range. 
 
2.4 Results and Discussion 
The quantitative determination of vitamin D and its metabolites in milk is a challenging task. 
Low abundance of vitamin D in milk, its instability in the presence of heat and light, and the 
presence of interfering endogenous components in milk were key challenges. Initially, we 
embarked in analysing the same four major analogues as in a published method available for 
milk, D2, D3, 25(OH)D2 and 25(OH)D3 (135) and 3-epi-25(OH)D3 and optimised the 
derivatisation step for these compounds. Following the initial development we used targeted 
multiple reaction monitoring (MRM) using predicted molecular ions and predicted fragment 
ions for number of other known vitamin D analogue-PTAD derivatives: 652-378 (D2-S), 640-
378 (D3-S), 650-378 (25(OH)D2-S), 639-378 (25(OH)D3-S), 586-314 (1,25(OH)2D2), 574-
314 (1,25(OH)2D3), 586-298 (24,25(OH)2D2) and 574-298 (24,25(OH)2D3). From this study, 
we screened 1,25(OH)2D2, 1,25(OH)2D3, 24,25(OH)2D2 and 24,25(OH)2D3 therefore 
purchased standards for the confirmation of identities and subsequently the stable isotope 
labelled analogues to use as internal standards for quantification purposes. Subsequent 
optimisation studies included all eight analogues. Although sulfated forms of Vitamin D were 
not screened in this study, unlabelled and deuterium-labelled sulfated standards were also 
acquired for further investigations.         
 
2.4.1 MS optimisation 
The MS parameters were optimised by directly infusing the vitamin D-PTAD derivatives into 
MS detector. Initially, the derivatisation was carried out using 11,000-fold molar excess of 
PTAD relative to vitamin D, as commonly noted in previous studies (36). We were unable to 
detect signals for any of the vitamin D compounds. We considered that ionisation suppression 
by the excess PTAD reagent may have been responsible for this observation and we 
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subsequently used a 5-fold molar excess of PTAD, thereby obtaining good signals and 
validating our hypothesis. ESI in positive mode was used to identify the precursor and 
product ions to be used for quantification in order to develop an MRM method. Two product 
ions were obtained for each vitamin D-PTAD derivative, the predominant product ion was 
used as the quantifier ion and the other as the qualifier ion. These ions were detected with 
high sensitivity and selectivity and resulted from the moiety where PTAD is attached to the 
cis-diene moiety of the A-ring and the double bond of the opened B ring of vitamin D 
compounds. Compound dependent parameters such as fragmentor and collision energies were 
tuned to produce the most intense mass spectral signals for each analyte, as shown in Table 3. 
Dehydrated precursors [M-H2O+H]
+
 were selected for most of the vitamin D-PTAD 
compounds (producing the m/z 298, 314 and 378 fragments) as their abundances were higher 
than those of the protonated molecules ([M+H]
+
). These compounds commonly lose a 
molecule of water at position 25, which is attributed to the formation of a stable tertiary 
carbocation (36, 43). For all other vitamin D-PTAD derivatives, the highest signal response 
was dominated by [M+H]
+
 (producing the m/z 298, 365 and 378 fragments). As shown in 
Figure 4, the source parameters were also optimised in order to maximise the ESI response of 
each targeted analyte.  
 
Figure 4. Optimisation of source parameters. 
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2.4.2 LC optimisation 
Chromatographic separation for all vitamin D compounds was optimised with emphasis on 
baseline separation of the critical isomeric pair: (25(OH)D3 and 3-epi-25(OH)D3). Another 
concern was the potential interference of 7-DHC in the quantification of D3 because these 
compounds also possess the same molecular mass. In order to conduct these separations, a 
range of chromatographic columns were tested including, PFP (as listed in experimental 
section), and C18 columns with a range of particle sizes. Organic modifiers such as, 
methanol, acetonitrile and isopropanol were also tested in different ratios and combinations. 
Unreacted, excess PTAD was observed (using Total Ion Current, TIC mode of MS) eluting 
early in the chromatogram; we therefore ensured that all vitamin D compounds eluted clear of 
the excess PTAD. Using lengthier retention times also ensured elimination of the matrix 
effects from the endogenous interferences, eluting early in the chromatographic separation. 
The optimal separation was achieved with isocratic-gradient conditions using methanol/water 
(with 0.1% formic acid) as mobile phase on a C18 column with a particle size of 2.7 µm. This 
mobile phase demonstrated the superior selectivity of the C18 column, with a small particle 
size, toward vitamin D compounds and particularly for the critical pair (25(OH)D3 and 3-epi-
25(OH)D3), as shown in Figure 5. 
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Figure 5. Chromatographic separation of the major (derivatised) vitamin D forms, 
including 7-dehydrocholesterol, as described in the experimental section. 
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The use of tandem mass detection and satisfactory chromatographic separation ensured the 
high specificity of the method. Although methanol as an eluent created higher column 
backpressures due to its greater viscosity compared to acetonitrile, it also produced superior 
selectivity. The optimal column temperature was found to be 40 
o
C. All vitamin D-PTAD 
derivatives in the mixture were chromatographically resolved from each other; except for D2 
and D3. However, these were easily distinguished from each other based on their MRM 
transition pairs, and the use of co-eluting internal standards for each corrected the effects of 
ion suppression/enhancement from each other. The isomers (R and S) of some compounds 
were not separated under our chromatographic conditions, which also agree with previous 
methods (36, 43, 100). Because we used the total peak area of both forms for quantification, 
the separation or non-separation of R and S isomers does not affect the quantification 
outcome. 
 
2.4.3 Optimisation of derivatisation reaction with PTAD 
Some studies have reported previously that the detectability of vitamin D compounds was 
improved about 100-fold after the derivatisation (36, 88), whereas others saw improvements 
of about 20-fold (100). The molar ratios of PTAD:vitamin D used in reported methods varied 
from 11,000:1 to 571,000:1, and the reaction time varied from 1 to 4 h (36). The results of 
our optimisation are shown in Figure 6.  
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Figure 6. Signal responses for vitamin D analogues with different derivatisation 
conditions, as described in the experimental section. 
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Clearly, a 10,000-fold excess of PTAD with one-hour reaction time proved to be the optimum 
derivatisation conditions, giving rise to the best sensitivity, for all five analogues. One hour 
was found sufficient to complete the reaction between PTAD and all vitamin D compounds, 
which agrees with literature reports (88). Table 4 shows the relative response factors, RRF, 
obtained using peak height ratio of the signal and noise for each analogue calculated relative 
to the highest peak (D2-PTAD in this instance), for derivatised and underivatised forms. It 
also shows the ratio of the RRF values of derivatised/underivatised forms.  
 
Table 4. Relative response factor (RRF) values obtained for derivatised and non-derivatised 
forms, and the ratios of the two, as described in text. 
 
Compound Sensitivity (S/N) 
PTAD 
Sensitivity (S/N) 
Non-PTAD 
Gain (x-fold)  
D2 100 1.67 60 
D3 78.3 0.97 80 
25(OH)D2 41.4 0.82 50 
25(OH)D3 58.7 1.04 56 
3-epi-25(OH)D3 45.4 0.90 50 
 
These results indicate that the ionisation efficiencies have been improved some 50-80-fold, 
following derivatisation with PTAD, using the optimised method. In addition to the 
detectability, the chromatography (on C18) and the stability of the vitamin D analytes were 
also improved significantly over the unreacted forms. As the derivatisation shifted the m/z 
range of the reacted forms to higher m/z values, it reduced the significant chemical 
background that is usually present in low m/z regions. The background noise was therefore 
reduced substantially over the unreacted forms giving rise to a higher signal/noise ratio, as 
shown in the Figure 7.  
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Figure 7. Chromatographic profile of each targeted compound before and after PTAD 
derivatisation. 
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The peak areas of derivatised forms that were exposed to light at room temperature for 8 h 
were not significantly different from those of unexposed to light, indicating the light stability 
of the derivatised forms (data not shown). PTAD has been reported to generate ketones from 
secondary alcohols of vitamin D metabolites (36); however, this phenomenon was not 
observed. Since PTAD is unstable in protic solvents such as water (36), a range of different 
types of ACN were evaluated for the lowest possible quantity of water: anhydrous, dried 
(using molecular sieves) and HPLC grade. As shown in the Figure 8, no significant 
differences were observed when using different types ACN. Hence, further studies were 
carried out using ACN (HPLC grade); this solvent is cheaper and the preparation less 
laborious compared with the other types of ACN tested. 
 
 
Figure 8. Comparison of different ACN types for PTAD derivatisation. Error bars 
represent ±1sd. 
 
2.4.4 Optimisation of sample preparation 
The efficiencies of two methods (PP and SN) were evaluated by comparing the concentration 
of each form of vitamin D detected in human milk. The SN procedure was adapted from 
previous analytical methods for analysis of vitamin D in milk (123). A PP with acetonitrile 
was selected, based on its high deproteinisation efficiency (136). In our preliminary studies, 
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we found that the evaporation of solvent to dryness in PP (before the derivatisation) was 
tedious and time consuming leading to vitamin loss. To overcome this problem, an LLE 
procedure similar to that used in SN (29, 112) was incorporated, generating an evaporation 
step that was easier and faster. Furthermore, different ratios of hexane-dichloromethane were 
evaluated with both SN and PP and the hexane-dichloromethane (4:1, v/v) solution was found 
optimal; the extraction yield was increased for each compound, especially for the metabolites 
that are relatively more polar, as shown in the Figure 9.  
 
 
Figure 9. Comparison between different ratios of hexane and dichloromethane. Error 
bars represent ±1SD. 
 
The use of higher volumes of dichloromethane (4:2 or 4:4) or the omission of 
dichloromethane decreased the extraction yield. Both PP and SN were conducted using this 
optimised LLE on human milk (each in triplicate) and the results are shown in Figure 10.  
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Figure 10. Comparison between PP and SN procedures for the extraction of vitamin D 
from milk. Error bars represent ±1SD. 
 
Significantly higher amounts of vitamin D were obtained with PP compared to SN which has 
been the method of choice for milk until this study. SN is well known for its effects on 
vitamin loss (123) and compensatory approaches such as the use of cold SN and the addition 
of antioxidants (both employed in our study) were incorporated to minimise these effects. 
However, the comparison study demonstrates that despite the improvements, vitamin yields 
are lower with saponification. All further studies were carried out using protein precipitation; 
a method that was simpler, faster and more efficient in extracting the vitamin.  
 
2.4.5 Method validation 
The LOD and LOQ, estimated based on 3x and 10x noise respectively, ranged from 0.20 to 
2.86 fmol, as shown in Table 5.  
 
 
 
 
 
 
 
51 
 
Table 5. Linearity, and detection and quantitation limits for the vitamin D compounds. 
 
Compound Linearity (r
2
)  
&  
Upper limit (nM) 
LOD* 
(fmols) 
LOD** 
(pM) 
LOD*** 
(pM) 
LOQ* 
(femtomols) 
LOQ** 
(pM) 
LOQ*** 
(pM) 
D2 0.998 (5) 0.28 14 0.35 0.94 47 1.17 
D3 0.999 (5) 0.28 14 0.35 0.94 47 1.17 
25(OH)D2 0.998 (1) 0.20 11 0.27 0.76 38 0.95 
25(OH)D3 0.999 (5) 0.38 19 0.47 1.00 50 1.25 
1,25(OH)2D2 0.999 (0.5) 0.20 10 0.25 0.72 36 0.90 
1,25(OH)2D3 0.996 (0.5) 0.20 10 0.25 0.66 33 0.82 
24,25(OH)2D2 0.999 (1) 0.40 20 0.50 0.86 43 1.07 
24,25(OH)2D3 0.998 (5) 0.36 18 0.45 0.90 45 1.12 
D2-S-PTAD  0.999 (0.5) 0.74 37 0.92 2.52 126 3.15 
D3-S-PTAD  0.996 (0.5) 0.56 28 0.70 2.60 130 3.25 
25(OH)D2-S-PTAD  0.996 (0.5) 0.86 43 1.10 2.86 143 3.57 
25(OH)D3-S-PTAD  0.996 (1) 0.60 30 0.75 2.00 100 2.50 
 
*On column amounts 
** Concentration in extract 
*** Concentration in milk 
 
Table 5 also shows LOD and LOQ values calculated based on the concentrations of the 
extract that was injected to the column (with the volume of injection of 20 µL), and the 
concentrations in milk (based on 40-fold concentration in the extract). Since isotopically 
labelled analogues (as internal standards) possess chemical behaviours similar to the 
corresponding analyte, they are expected to compensate for any sample losses and/or 
suppression effects that may take place during sample processing and analysis (119, 137, 
138). Another advantage of using such internal standards is that it has been previously shown 
that there is no significant difference in the results when calibration standards are prepared 
either in mobile phase solvent or in matrix matched medium, when isotopically labelled 
standards are used as the internal standards (119, 139). Therefore, in our study, the calibration 
standards were prepared in mobile phase solvent (the starting composition of the run), as 
described in the experimental section. Calibration standards (six levels) were prepared to 
include the typical levels of each form reported in milk, as described in the experimental 
section. Table 6 shows the linearity, along with the upper limits of concentrations used in this 
study. Good linearities (r
2
 of >0.99) were obtained for all analogues for the required 
concentration ranges. The repeatability values (n = 10), determined by analysing multiple 
aliquots of the same human milk sample on the same day and expressed as percentage 
standard deviations, are shown in Table 6.  
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Table 6. Repeatability and recovery for the targeted vitamin D compounds. 
 
Compound Repeatability (n=10) Recovery (n=6) 
Mean ± SD (pM)* RSD (%) Mean ± SD (%) 
D2 8.14 ± 0.001 6.30 93.9 ± 3.23 
D3 12.2 ± 0.002 13.2 98.9 ± 6.83 
25(OH)D2 2.38 ± 0.001 9.36 95.8 ± 8.02 
25(OH)D3 16.7 ± 0.001  4.77 98.2 ± 2.27 
1,25(OH)2D2
** 
0.305 ± 0.004 13.0 88.2 ± 3.99 
1,25(OH)2D3 1.22 ± 0.001 9.75  94.5 ± 10.5 
24,25(OH)2D2 1.38 ± 0.004 13.5 96.5 ± 8.25 
24,25(OH)2D3 7.74 ± 0.005 7.68 105 ± 8.29 
D2-S-PTAD  ----- ----- ----- 
D3-S-PTAD  ----- ----- ----- 
25(OH)D2-S-PTAD  ----- ----- ----- 
25(OH)D2-S-PTAD  ----- ----- ----- 
 
* Concentration in milk 
** Approximate only (value between LOD and LOQ) 
 
The method is precise with percentage standard deviations within the range 4.76-13.5. The 
mean recoveries, calculated using the percent ratio of observed/spiked concentrations, were 
in the range of 88.2-105%, as shown in Table 8. The method was applied to measure eight 
analogues of vitamin D in human, cow, mare, goat and sheep milk. The sulfate forms were 
not detected in the milk samples. The chromatographic profiles obtained for human milk are 
shown in Figure 11.  
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Figure 11. Chromatographic profile of the major vitamin D forms (derivatised) in 
human milk. 
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The concentrations of each vitamin D compound quantified are listed in Table 7.  
 
Table 7. Concentration of vitamin D compounds in milk samples from human, cow, goat, 
mare and sheep. 
 
Compound (pM) Human Cow Mare Goat Sheep 
D2  8.63 5.70 ---- 3.36 ---- 
D3  13.0 14.1 14.5 12.6 13.9 
25(OH)D2  2.34 1.90 ---- 1.68 ---- 
25(OH)D3  16.0 19.7 13.1 10.9 11.9 
1,25(OH)2D2  0.31 ---- ---- ---- ---- 
1,25(OH)2D3  1.14 0.41 ---- ---- ---- 
24,25(OH)2D2  1.27 0.94 ---- 0.86 ---- 
24,25(OH)2D3  7.68 10.7 7.09 7.94 4.69 
              
 
Vitamin D3 and 25(OH)D3 are the major forms in all species. There may be similarities in the 
relative levels of each analogue in different species, however, more work is needed to study 
this trend. It is also important to consider that the content of vitamin D may vary significantly 
due to factors such as vitamin D supplementation, exposure to sunlight, and storage 
conditions. 
 
2.5 Conclusions  
Despite the lack of accuracy, reproducibility and selectivity of immunoassays, they have been 
the only methods readily available for the quantification of the dihydroxyl vitamin D forms in 
milk. The scope of the LC-MS/MS methods available for milk has been limited to the 
quantification of D2, D3, 25(OH)D2 and 25(OH)D3. The method reported here has expanded 
the scope to include four additional analogues. The contribution of the inactive form 3-epi- 
25(OH)D3 has been (chromatographically) removed to prevent overestimation of vitamin D. 
Adequate retention was achieved for all analytes of interest to minimise the ion suppression 
effects from early eluting endogenous compounds and excess derivatising agent. The 
maximum possible sensitivity and specificity for each of the eight (derivatised) analogues has 
been obtained by optimisation of the ESI source and MRM conditions. The PTAD 
derivatisation was systematically optimised for pre-column derivatisation. It should be noted 
that the optimisation of the MS conditions, chromatography, and the derivatisation method 
are applicable to matrices other than milk, permitting femtomole levels of vitamin D 
compounds to be quantifiable. The protein precipitation method, with some modifications, 
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has been applied to milk for the first time and found superior to the commonly used 
saponification in terms of efficiency of extraction, simplicity and speed. By using an isotope 
labelled internal standard for each vitamin D compound we have developed an accurate as 
well as a specific and sensitive quantification method for these compounds. The method 
presented here was unable to capture sulfated forms in milk samples. This finding may be 
attributable to the strongly acid characteristics of the sulfate moiety that would facilitate 
deprotonation rather than protonation in the mass spectrometer. In this context, PTAD 
derivatisation would not be required to improve their ionisation efficiencies, as these 
compounds could be readily negatively ionised in solution at a typical pH range. Thus, the 
ionisation efficiency of the sulfated forms (unreacted in negative mode ESI) will be evaluated 
and further compared with those from PTAD derivatives in positive mode ESI. 
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3 Chapter 3: Effect of pasteurisation on the concentrations of vitamin D 
compounds in donor breastmilk 
  
3.1 Foreword 
This chapter describes the effect of pasteurisation on the vitamin D content in donor 
breastmilk. The analytical method developed and validated in chapter 2 was used for this 
study. The content of this chapter has been published in the International Journal of Food 
Sciences and Nutrition, 67: 16–19 (2016) and it is presented in a slightly altered format to fit 
with the style of this thesis. Permission was granted from the publisher to reproduce the work 
in this thesis. 
 
3.2 Introduction 
Breastmilk is the most important nutrient and source of supplementation for both term and 
preterm infants (140). It is composed of many important nutrients, including vitamin D (4). 
The content of this vitamin in breastmilk is usually low, even for lactating mothers with 
adequate vitamin D status (4, 141). Preterm infants are at a significant risk of vitamin D 
deficiency due to decreased transplacental transfer (142, 143). Such infants also possess 
smaller vitamin D storage sites such as fat and muscle tissue (144). Vitamin D is essential for 
the regulation of the intestinal absorption of calcium and phosphate, both of which are vital 
for healthy homeostasis (13, 123). When mothers are unable to breastfeed their infants, 
pasteurised donor human milk (PDHM) is considered to be the most effective alternative 
source of nutrition (145) and it is widely accepted that donor human milk has considerable 
advantages over formula milk (146). Donor human milk is collected, processed and stored by 
specialised centres, such as human milk banks (147). Donor breastmilk is obtained from 
healthy lactating mothers who consent to donate their surplus breastmilk (147, 148) and this 
milk is pasteurised to reduce microbial growth, ensuring its safety for infant consumption 
(149). The most common pasteurisation procedure is known as Holder pasteurisation (HP), in 
which milk is exposed to a temperature of approximately 62.5
o
C for at least 30 min (145). 
While this thermal procedure is required to minimise potential infectious diseases, it may be 
responsible for the destruction or degradation of vitamin D, since this vitamin is potentially 
sensitive to high temperatures (148). Vitamins D2 and D3 (D2 and D3) and the metabolites 25-
hydroxyvitamins D2 and D3 (25(OH)D2 and 25(OH)D3) are the four major forms of vitamin D 
compounds in biological fluids (150). It has been suggested that D3 is more efficiently 
intestinally absorbed than D2 (124, 125). The metabolite 25(OH)D3 has three times the 
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potency (126) and higher affinity than 25(OH)D2 to vitamin D-binding protein (DBP), which 
results in higher half-life (124). Some studies on the effect of pasteurisation have been 
reported, including, for example the significant effects of pasteurisation on the content of 
vitamin C in milk (148, 151, 152). To our knowledge, however, no investigations on the 
impact of pasteurisation upon the vitamin D content in breastmilk have been reported. The 
aim of this study was to evaluate the effect of pasteurisation on the content of D2, D3, 
25(OH)D2 and 25(OH)D3 in donor breastmilk. The quantitative determination of vitamin D 
and its metabolites in milk is a challenging task due to their low levels and the presence of 
interfering endogenous components. A published liquid chromatography mass spectrometry 
(LC-MS/MS) method previously developed and validated for the analysis of a wide range of 
vitamin D analogues in milk was used to evaluate the effect of pasteurisation on the above 
compounds in donor breastmilk (150).
 
  
 
3.3 Methods 
3.3.1 Collection 
Breastmilk samples were donated by 16 healthy lactating women. Participants were women 
(over 18 years old) who wished to donate milk to the Milk Bank at the Royal Brisbane & 
Women’s Hospital (RBWH) and who had met the criteria to donate. The milk bank staff 
asked the volunteers during the routine interview whether they would be interested in 
participating in this study. Information sheets were provided to all potential participants and 
all questions were addressed. Informed consent was provided by all donors to use their 
breastmilk in this research work; all information linking the samples with specific donors was 
removed from the samples. The collection of the milk samples from RBWH was approved by 
RBWH ethics committee and The University of Queensland (UQ) ethics committee. A 
RBWH Milk Bank has been established for two years; its processes are based on the Good 
Manufacturing Practice guidelines and it is accredited with ISO 22000 (153). A four millilitre 
aliquot was used to analyse vitamin D levels (pre-pasteurisation) and another four millilitre 
aliquot was used to analyse vitamin D levels (post-pasteurisation). Each aliquot was placed in 
a clean Eppendorf tube and given a unique identifier. The milk samples were stored at -80
o
C 
until analysis.  
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3.3.2 Holder-pasteurisation 
The breastmilk samples were processed in a Sterifeed Pasteuriser. An aliquot of each 
breastmilk sample was transferred into a bottle and submitted to a pre-heated water bath 
(62.5
0
C) for 30min (153). 
 
3.3.3 Chemicals 
The unlabelled and labelled standards (D2, D3, 25(OH)D2 ,25(OH)D3, D2-d3, D3-d3), were 
purchased from IsoSciences (King of Prussia, USA), and (25(OH)D2-d6 and 25(OH)D3-d6) 
from Chemaphor (Ottawa, Canada). All compounds had a purity of 97% or better. PTAD 
(≥97%) was purchased from Sigma Aldrich (St. Louis, USA). The organic solvents of LC-
grade (dichloromethane, ethanol, hexane, acetonitrile and methanol) were purchased from 
Merck (Darmstadt, Germany). LC-MS grade formic acid (>99%) was purchased from Fisher 
Chemical (Geel, Belgium). High-purity water was prepared by using a Millipore Milli-Q 
system (Milford, USA).  
 
3.3.4 Sample preparation and LC-MS/MS analysis 
The milk samples were processed and analysed according to an established LC-MS/MS 
method for the analysis of a range of vitamin D analogues in milk (150).
 
 
 
3.3.5 Statistical analysis 
The results are presented as a percentage increase or decrease of each analyte post-
pasteurisation, compared with pre-pasteurisation. Statistically significant differences were 
assessed by comparing pre- and post-pasteurisation values using the Wilcoxon matched-pairs 
signed rank test, with P<0.05 considered significant, calculated using Prism 6 
(GraphPad.com). 
 
3.4 Results 
Pasteurisation resulted in a significant reduction (P< 0.05) in the content of D2, D3, 
25(OH)D2 and 25(OH)D3 with P values of 0.01 for all targeted analytes. The individual pre- 
and post-pasteurised sample values are illustrated in the Figure 12.  
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Figure 12. The individual pre- and post-pasteurised sample values. 
 
The mean concentrations of the vitamin D analogues in non-pasteurised milk were 4.1 pM 
(D2), 4.2 pM (D3), 1.6 pM (25(OH)D2) and 3.6 pM (25(OH)D3), as shown in Table 8.  
 
Table 8. Mean/median concentrations (pM) of vitamin D compounds (pre- and post-
pasteurisation). Samples of donor breast milk (n=16) were analysed by LC-MS/MS. 
 
The mean concentrations of the vitamin D analogues in post-pasteurised milk were 3.5 pM 
(D2), 3.8 pM (D3), 1.3 pM (25(OH)D2) and 3.1 pM (25(OH)D3), as shown in Table 10. 
Losses of vitamin D compounds caused by pasteurisation ranged from 10% to 20%.  
 
Compounds Pre-pasteurised Post-pasteurised Pre-pasteurised Post-pasteurised 
 Mean ± SD  Mean ± SD  Median (95% CI)  Median (95% CI)  
D2 4.1 ± 0.45 3.4 ± 0.36 4.0 (3.7 - 4.5)  3.3 (3.2 - 3.9) 
D3 4.2 ± 2.41 3.8 ± 2.36 3.4 (2.3 - 6.4) 3.0 (2.3 - 6.0) 
25(OH)D2 1.6 ± 0.23 1.3 ± 0.14 1.6 (1.4 - 1.7) 1.3 (1.2 - 1.4) 
25(OH)D3 3.3 ± 2.20 3.1 ± 2.16 3.1 (1.8 - 5.0) 2.4 (1.4-  4.7) 
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3.5 Discussion 
This study assessed the effect of pasteurisation on key vitamin D compounds in donor 
breastmilk. Isotopically labelled analogues of each standard compound were used as internal 
standards to ensure the reliability of the results, provided by the LC-MS/MS method (119). 
As expected, the concentrations of D2, D3, 25(OH)D2 and 25(OH)D3 in breastmilk were 
found to be at very low (picomolar) levels, and within the levels reported previously (135, 
150). 
 It is important to note that vitamin D supplementation and seasonal variation may impact 
significantly on the vitamin D content in breastmilk (141). Other metabolites such as 1,25-
dihydroxyvitamin D3 (1,25(OH)2D3) and 24,25-dihydroxyvitamin D3 (24,25(OH)2D3) were 
also detected in some samples. A statistical evaluation was not possible with these 
metabolites due to the very low levels detected in three samples. The epimeric form of 
25(OH)D3 was detected in two samples. Since these two isomers were chromatographically 
resolved, there was no over-estimation of the 25(OH)D3 status. The method used for this 
study was capable of only removing the inactive epimeric form from 25(OH)D3 but not of 
quantifying it. Therefore, the effect of pasteurisation on the inactive epimer was not studied. 
In this study, we have observed that D2, D3, 25(OH)D2 and 25(OH)D3 concentrations were 
decreased after pasteurisation, indicating that donor breastmilk has potentially a reduced 
antirachitic activity when compared to breastmilk provided directly from a lactating mother. 
As these compounds cannot be protected from temperature changes during the pasteurisation 
process, their partial destruction or isomerisation to inactive forms may be unavoidable when 
using such thermal methods. Vitamin D compounds are potentially thermally sensitive, as 
observed by their decomposition upon exposure to heat in the presence of air (154) and these 
substances can be converted irreversibly to cyclised compounds such as, pyro- and isopyro-
vitamin D at elevated temperatures (155-158). Cooking temperatures in absence of either air 
or light have been found to promote the isomerisation of vitamin D to pyro-vitamin D (158). 
This vitamin can be also thermally converted to its precursor form (159).  
Our results demonstrate that vitamin D2 compounds were more affected by pasteurisation 
than were the D3 vitamin compounds, indicating their higher sensitivities to thermal 
treatments. Hence, the measurement of either D2 or 25(OH)D2 may be potentially regarded as 
a suitable indicator of the degree of thermal treatment, although D2 was less affected than 
25(OH)D2. Another potential source of vitamin loss could have been the adsorption of the 
vitamin D and/or fat to the pasteurisation vessel; the significance of this effect is not yet 
known and is a focus of future studies. In general, the activities of vitamins are expressed in 
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international units (IU). With vitamin D, both cholecalciferol and ergocalciferol are 
considered to have a similar potency: 1IU = 25 ng. The content of vitamin D in breastmilk is 
usually very low (about 20 IU/L) (4). As a result, it is often unable to satisfy the current 
vitamin D recommendations and hence meet the specific needs of premature infants. It has 
therefore been suggested that preterm infants should be supplemented with vitamin D (160). 
There appears to be little consensus for the optimal daily intake of vitamin D for preterm 
infants (161) and vitamin D intake has been suggested to be about 400 IU a day (162). In the 
case of full term infants who receive donor milk, the adequacy of vitamin levels of the donor 
milk and hence intake are provided with less attention than those of premature infants. The 
results of our study, therefore, may have more impact on those full term infants dependent on 
pasteurised donor milk. 
 
3.6 Conclusions  
We have demonstrated that the content of vitamin D compounds in donor breastmilk is 
consistently very low when compared to some recommendations of dietary requirements and 
these concentrations are also affected by pasteurisation. Further research work is required to 
establish the biological implications related to these findings. Since many milk banks have 
now been established across the world, it is timely and also essential to evaluate the content 
of vitamin D in pasteurised donor breastmilk with reliable analytical tools such as LC-
MS/MS. This approach will then ensure that health care can be provided based on reliable 
values to establish adequate vitamin D supplementation or/and milk fortification. This study 
has provided preliminary data that can be used for the improvement of current approaches for 
milk pasteurisation treatments, permitting minimal effects on the biological activity of 
vitamin D in breastmilk.      
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4 Chapter 4: Development and validation of a method for the quantification of 
four sulfated vitamin D compounds in breastmilk and human serum by liquid 
chromatography-tandem mass spectrometry 
 
4.1 Foreword 
The aforementioned LC-MS/MS method (chapter 2) failed to accommodate both fat- and 
water soluble forms of vitamin D. It was only capable of determining fat-soluble forms.  This 
chapter describes a new approach taken to analyse the water-soluble forms. A comparative 
evaluation of the ionisation efficiencies of the underivatised forms of sulfates in negative ion 
mode ESI and those of the derivatised (using PTAD) forms in positive ion mode ESI was 
carried out. Based on this comparison, a sensitive LC-MS/MS method was developed, and 
validated. The content of this chapter has been published in the Journal of Chromatography 
B, 1009: 80-86 (2016) and it is presented in a slightly altered format to fit with the style of 
this thesis. Permission was granted from the publisher to reproduce the work in this thesis. 
 
4.2 Introduction 
It has been commonly accepted that vitamin D has a much wider role to play in the human 
organism rather than just its role in the homeostasis of healthy bone tissues. A growing body 
of evidence has been provided on the importance of this vitamin, in reducing the risk of 
hypertension, common cancers, diabetes mellitus, autoimmune and cardiovascular disorders 
(4, 13). Despite these findings, vitamin D deficiency still remains a commonly encountered 
health issue, affecting many individuals across the world (123).  
While both fat- and water-soluble forms of vitamin D have been reported in diverse 
biological fluids, clinical and nutritional attention has been primarily given to the fat-soluble 
forms (123, 163). Consequently, clinical studies on water-soluble Vitamin D compounds are 
lacking. It has been suggested that the water-soluble forms (sulfate conjugates) of vitamin D 
have potencies similar to those of the fat-soluble compounds (20). Although the biosynthesis 
of the sulfates is unclear (19), a study has shown that vitamin D is not readily sulfated in man, 
indicating its formation from a conjugated precursor is possible (22). The presence of 7-
dehydrocholesterol-sulfate (7-DHC-S) has been reported in human and rat skin tissue, 
confirming the existence of a precursor for vitamin D3-sulfate (D3-S) (19). While controversy 
exists regarding the specific actions and biological roles (164), it has been reported that 
vitamin D3-sulfate (D3-S), when orally administered in high doses, increases calcium 
transportation in young rats (23).  
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25-Hydroxyvitamin D3-sulfate (25(OH)D3-S) is a major circulating form of vitamin D and its 
levels in human blood may exceed those of the non-sulfated form, 25(OH)D3 (19, 22), the 
most commonly measured form of vitamin D used to determine vitamin D status (123). 
Clearly, the measurement of 25(OH)D3-S in human blood is thus likely to be important in the 
assessment of vitamin D status. 25(OH)D3-S could be considered a storage form of non-
sulfated D3, as hydrolysis of the conjugate may potentially take place in vivo (19, 21).  
Vitamin D2-sulfate (D2-S) has been detected in chicken tissues and in rabbit urine (23, 165) 
and the biosynthesis of D2-S has been achieved in vitro (165). It has also been demonstrated 
that D2-S possesses a potent antirachitic activity when administered in rats (24).  
To our knowledge, the vitamin D metabolite, 25-hydroxyvitamin D2-sulfate (25(OH)D2-S), 
has not yet been reported in biological fluids, and its physiological functions are unknown. In 
fact, the vital roles of D-S forms are still debatable and clear evidence for their biological 
function in humans has not yet been reported. A potential reason for this is the absence of a 
sufficiently sensitive analytical method to detect endogenous levels of these compounds.  
Methods based on low sensitivity and low specificity, such as colorimetry, have been 
reported for the analysis of D-S analogues in milk (166, 167). Contradictory results were 
obtained in different studies for D-S in breastmilk (168), which may be due to a lack of 
specificity in the analytical methods used and that saponification has been used as an 
extraction procedure for D-S in milk (169). Although widely used to extract vitamin D 
analogues from food, saponification may be especially destructive for the water-soluble 
forms of this vitamin (167, 168).  
Hyphenated methods such as liquid chromatography-UV spectrophotometry (LC-UV) have 
been used for the measurement of D3-S and 25(OH)D3-S (22, 164, 170). They have been 
largely replaced by liquid chromatography-tandem mass spectrometry (LC-MS/MS), 
currently considered the technique of choice for vitamin D assays (171). Although LC-
MS/MS offers the resolving power of LC systems combined with the high sensitivity and 
specificity of MS/MS detection, two major problems are associated with this technique in 
vitamin D assays. Firstly, vitamin D compounds have poor ionisation efficiencies when using 
atmospheric pressure ionisation (API), which has been solved by derivatising them with 4-
phenyl-1,2,4-triazole-3,5-dione (PTAD) or other Cookson type reagents (described in the 
chapter 1) (123, 171). Secondly, the susceptibility of MS detection to matrix effects such as 
ionisation suppression can negatively compromise the quality of assay, in terms of sensitivity 
and accuracy. This has been resolved by the use of a high efficiency separation method to 
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minimise co-elution and by the use of co-eluting stable isotope labelled analogues as internal 
standards (123).  
The scope of currently available LC-MS/MS methods for the determination of sulfated 
vitamin D analogues is limited only to 25(OH)D3-S in human plasma (163). Therefore, we 
embarked on the development and validation of an LC-MS/MS method for the determination 
of four sulfated forms, D2-S, D3-S, 25(OH)D2-S and 25(OH)D3-S in breastmilk and human 
serum. A simple protein precipitation technique was used as the sample preparation method 
to remove the targeted analytes from the biological matrices and stable isotope labelled 
analogues of each targeted form were used as internal standards for accurate quantification. 
The ionisation efficiencies of the intact forms in negative ion mode electrospray (ESI) were 
compared to those of the derivatised forms with PTAD in positive ion mode ESI. The aim of 
this study was to develop a simple, effective and reliable method to quantify the water-
soluble forms of vitamin D in biological fluids.  
 
4.3 Material and methods 
4.3.1 Chemical and reagents 
The unlabelled and deuterium-labelled standards: D2-S, D3-S, 25(OH)D2-S, 25(OH)D3-S, D2-
S-d3, D3-S-d3, 25(OH)D2-S-d3, and 25(OH)D3-S-d3 were purchased from IsoSciences (King 
of Prussia, USA). All compounds had a purity of 97% or better. PTAD (≥97%) was 
purchased from Sigma Aldrich (St. Louis, USA). Organic solvents of LC-grade (acetonitrile 
and methanol) and analytical grade (ethanol) were purchased from Merck (Darmstadt, 
Germany). LC-MS grade formic acid (>99%) was purchased from Fisher Chemical (Geel, 
Belgium). LC-MS grade ammonium formate (>99%) was purchased from Sigma-Aldrich (St. 
Louis, USA). High-purity water was prepared by using a Millipore Milli-Q system (Milford, 
USA). Human milk samples were kindly donated by the breastmilk bank of the Royal 
Brisbane and Women’s Hospital (RBWH), Brisbane, Australia. Serum samples for the study 
were obtained from volunteer donors of the School of Pharmacy, The University of 
Queensland. Ethical approvals were obtained from the Institutional Human Research 
Department, The University of Queensland and from the Royal Brisbane and Women’s 
Hospital. 
 
4.3.2 LC-MS/MS analysis 
Chromatographic separations were carried out using an Agilent binary LC system consisting 
of an Agilent 1290 infinity LC pump, an Agilent 1290 well plate auto-sampler and a 
65 
 
Poroshell 120 EC-C18 (150 x 2.1 mm, 2.7 μm) column (Agilent Technologies, Santa Clara, 
CA, USA). An Agilent 6460 Triple Quadrupole tandem mass spectrometer equipped with a 
Jet Stream source and supported by Mass Hunter Workstation software (Agilent 
Technologies, Santa Clara, CA, USA) was used as the detector. 
A binary solvent system consisting of 10mM ammonium formate in water (A) and 10 mM 
ammonium formate in methanol (B) was used for separation. Gradient elution was used for 
the first 7 min (85 to 100% B), and remained at 100% B for the next 5 min. The composition 
returned to 85% B during the next 1 min, and the column was then re-equilibrated with 85% 
B for 10 min before injecting the next sample. The total run time including re-equilibration 
step was 23 min. The flow rate was 0.2 mLmin
-1
 and the injection volume was 20 μL. 
Mass spectrometry parameters such as fragmentor and collision energy were optimised to 
obtain the highest possible sensitivity for each compound, as shown in Table 9.  
 
Table 9. Optimised mass spectrometry parameters used in MRM mode for all vitamin D 
analogues. 
 
Table 9 also shows the m/z of precursor and product ions used in multiple reaction 
monitoring (MRM) mode for each D-S compound. Source parameters such as gas flow, 
sheath gas flow, gas temperature and sheath gas temperature were optimised and maintained 
at 5 L/min, 12 L/min, 300
o
C and 250
o
C respectively. The capillary and nozzle voltages were 
maintained at 5000 and 2000 V respectively. 
The derivatised forms were analysed using a previously developed method in our laboratory 
(chapter 2) (150). The detection parameters used in MRM mode are: D2-S-PTAD, m/z 652-
Compound Precursor ion 
(m/z) 
Product ion 
(m/z) 
Fragmentor 
(V) 
Collision energy  
(V) 
D2-S 475 96 242 32 
D2-S-d3 477 96 242 32 
D3-S 463 96 232 36 
D3-S-d3 465 96 232 36 
25(OH)D2-S 491 96 222 40 
25(OH)D2-S-d3 493 96 222 40 
25(OH)D3-S 480 96 222 36 
25(OH)D3-S-d3 482 96 222 36 
D2-S-PTAD 652 378 134 16 
D3-S-PTAD 640 378 124 12 
25(OH)D2-S-PTAD 650 378 154 12 
25(OH)D3-S-PTAD 639 378 144 12 
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378; D3-S-PTAD, m/z 640-378; 25(OH)D2-S-PTAD, m/z 650-378 and 25(OH)D3-S-PTAD, 
m/z 639-378.  
 
4.3.3 Preparation of standard and sample solutions 
All sample and standard preparations were carried out under subdued light and standard 
compounds were dissolved in ethanol to obtain stock solutions (1 µM) that were stored at -20 
o
C. Working solutions were prepared by serial dilution from the stock solutions. Each 
breastmilk sample was vortex mixed and 4 mL aliquots were accurately measured and frozen 
until extraction and analysis. Each serum sample was vortex mixed and 250 µL aliquots were 
accurately measured and frozen until extraction and analysis. 
For milk samples, eight millilitres of acetonitrile were added to 4 mL milk and vortex mixed 
for 2 min. The samples were incubated at room temperature for 15 min to complete the 
protein precipitation, and then centrifuged for 10 min at 4000 g. The supernatant was 
transferred to a fresh centrifuge tube and evaporated under a gentle stream of nitrogen. After 
evaporating most of the acetonitrile, the remaining solution in the tube was frozen at -80 ͦ C. 
The frozen sample was then evaporated to dryness using a freeze drier operated at -80 ͦ C. The 
residue was reconstituted in 500 µL of mobile phase (85% B).   
For serum samples, a 500 µL aliquot of acetonitrile was added to 250 µL serum and vortex 
mixed for 2 min. The procedure was performed as described above for milk samples; 
however, the residue was reconstituted in 50 µL of mobile phase (85% B).  
For the analysis of derivatised forms of the standards and samples, a previously developed 
method in our laboratory was used (150). The derivatised and underivatised forms were 
prepared to obtain the same final concentrations.  
 
4.3.4 Comparison of positive and negative ESI ionisation methods using derivatised and      
underivatised forms 
The derivatised and underivatised forms of standard compounds (10 nM each in final 
solution) were analysed using separate LC-MS/MS procedures, as described above. Peak 
areas were used to compare the ionisation efficiencies in ESI positive ion mode (derivatised 
forms) and ESI negative ion mode (underivatised forms). Triplicate measurements were 
performed for each method. 
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4.3.5 Method validation 
Linearity was estimated using six mixed standard solutions, dissolved in mobile phase, with 
concentrations ranging from 0.05 to 200 nM (D2-S, D3-S, 25(OH)D2-S and 25(OH)D3-S). 
Each mixed standard solution contained 25 nM of internal standards (D2-S-d3, D3-S-d3, 
25(OH)D2-S-d3 and 25(OH)D3-S-d3). The linearity was assessed by plotting the peak area 
ratios of each unlabelled form and its respective labelled form versus the concentration of 
unlabelled standard. The limits of detection (LOD) and limits of quantitation (LOQ) for each 
compound were determined based on the concentrations (as peak heights) corresponding to 
3x noise and 10x noise respectively. Repeatability was estimated by analysing 10 individual 
aliquots of both breastmilk and human serum samples followed by the calculation of relative 
standard deviation of the concentrations. Recovery was determined by using the 
concentrations of each targeted analogue determined for six aliquots each of spiked and non-
spiked breastmilk and human serum samples. Each aliquot of milk and serum was spiked to 
give an added concentration similar to the mid-point of the calibration range. 
 
4.4 Results and discussion 
4.4.1 Method development 
Direct infusion in ESI negative ion mode was used for the identification of the precursor and 
product ions to be used for the development of MRM method. Deprotonated species ([M-H]
-
)
 
were selected as precursor ions for all D-S compounds. The predominant product ion 
observed was the sulfate group, m/z 96.9, for each D-S analogue, in agreement with a 
previous report (21). In addition, the collision-induced dissociation (CID) spectra of the 
water-soluble forms did not exhibit any other product ion, as the sulfate was the most stable 
dissociation product. As shown in table 11, compound dependent parameters such as collision 
energy and fragmentor voltage were optimised to yield the highest mass spectral signal for 
each compound. 
Chromatography was developed to elute all four underivatised sulfates within 10 minutes. 
Figure 12 shows the overlapped chromatograms of the derivatised and underivatised 
analogues on the same scale.  
68 
 
 
Figure 13. Overlapped chromatographic profiles of the vitamin D sulfates in negative 
(underivatised compounds) and positive (derivatised with PTAD) ESI modes, as 
described in the above Material and methods section. 
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Figure 14 shows the average peak areas obtained for the triplicate analysis with error bars.  
 
 
Figure 14. ESI responses (average peak areas) for D-S analogues in negative ion mode 
(underivatised) and positive ion mode (derivatised with PTAD), as described in the 
experimental section. Error bars represent ±1SD (n=3). 
 
Table 10 shows the average peak area ratios of underivatised/ derivatised forms. Clearly, a 
significantly higher (>10 times) ESI response was consistently observed for all underivatised 
forms, in negative ESI. 
 
Table 10. Peak area ratios obtained for underivatised (negative ion mode) and derivatised 
(positive ion mode) forms. 
 
 
 
 
 
 
 
As mentioned previously, Diels-Alder cycloaddition reaction with PTAD has been widely 
used to enhance the detection characteristics of fat-soluble forms of vitamin D in API sources 
(36, 75, 83, 88, 104). Their ionisation efficiencies are increased due to the polar 
Compound Ratio 
D2-S 11 
D3-S 14 
25(OH)D2-S 12 
25(OH)D3-S 10 
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characteristics of PTAD; thus, positive ion mode is the most effective manner to maximize 
the ESI response of these compounds (36). Although the introduction of this readily ionisable 
moiety (PTAD) has rendered improvements in the detectability for the lipid-soluble forms of 
Vitamin D of about 100-fold, this approach includes time-consuming sample processing steps 
not necessarily suited for routine clinical and nutritional analysis (36, 88, 171). Despite these 
limitations, PTAD derivatisation is widely used because the levels of vitamin D in biological 
fluids are very low and without derivatisation it is not possible to detect many analogues 
(123).  
We initially attempted to develop a method in positive ion mode (derivatised forms) for the 
simultaneous determination of both fat- and water-soluble forms of vitamin D (150): only 
25(OH)D3-S was detected at very low levels. We then examined the method applicability of 
both negative (underivatised forms) and positive (derivatised forms) ion modes in human 
serum analysis (same sample). Whilst it was possible to observe the presence of all four 
endogenous D-S analogues in negative ion mode, only 25(OH)D3-S was detected in positive 
mode (data not shown). The ESI response in positive ion mode for 25(OH)D3-S was 
approximately 90% lower than that obtained in negative ion mode. Also, high background 
noise was observed in the chromatograms obtained in positive ion mode.  
Unlike the non-sulfated forms of vitamin D, the sulfated forms are capable of producing a 
negatively charged ion, by de-protonation, in ESI due to the presence of the ionisable sulfate 
moiety (21). Since the conjugated sulfates are strong acids, deprotonated molecules would be 
formed in solution for all D-S forms that were fully ionised in the sample and in mobile 
phase. As a result, the signal responses of the targeted compounds for underivatised forms 
were significantly higher than those of the derivatised forms, as illustrated in the Figure 9, 
indicating that the ionisation efficiency is lower for compounds that still require ionisation by 
protonation. 
Following the above comparison, all further experiments were carried out only in negative 
mode; the method was simpler (not requiring the lengthy derivatisation step) and faster, yet 
more sensitive, and therefore well suited for high throughput analysis.  
 
4.4.2 Method validation and application 
In this study, co-eluting stable isotope labelled analogues of each compound were used as 
internal standards to correct for ion suppression/enhancement effects due to co-eluting 
impurities and to compensate for procedural errors (119). It has been clearly demonstrated 
that when isotopically labelled standards are used as internal standards, there is no significant 
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difference in the results when calibration standards are prepared either in mobile phase 
solvent or in matrix matched medium (119, 139, 150). The samples as well as calibration 
solutions were therefore prepared in mobile phase (85% B, being the mobile phase 
composition at the beginning of the gradient). Calibration solutions at six levels were 
prepared to cover simultaneously the expected concentrations of each form reported in 
breastmilk and human serum. For the analogues that were not reported, the same ranges as 
for those that are reported were used. As shown in table 11, the calibration curves were linear 
(r
2
 of >0.99) for each analyte over the concentration ranges used in this study. The on-column 
LOD and LOQ estimated based on 3x and 10x noise ranged from 0.20 to 0.28 fmol (LOD) 
and from 0.68 to 0.92 fmol (LOQ), respectively as shown in Table 11.  
 
Table 11. Linearity, and detection and quantitation limits for D-S compounds. LOD and 
LOQ for milk and serum samples were estimated from on-column values.  
 
Compound Linearity 
(r
2
)  
 
LOD 
* 
(fmol) 
LOD 
** 
(pM) 
LOD 
*** 
(pM) 
LOD  
**** 
(pM) 
LOQ 
*  
(fmol) 
LOQ 
** 
 (pM) 
LOQ 
***  
(pM) 
LOQ 
****  
(pM) 
D2-S 0.999  0.2 10 1.2 2.0 0.78 34 4.2 6.8 
D3-S 0.999  0.28 14 1.7 2.8 0.92 46 5.8 9.2 
25(OH)D2-S 0.996  0.24 12 1.5 2.4 0.78 39 4.9 7.8 
25(OH)D3-S 0.998  0.24 12 1.5 2.4 0.80 40 5.0 8.0 
 
*On column amounts 
** Concentration in extract 
*** Concentration in milk 
**** Concentration in serum 
 
The LOD and LOQ values were also estimated based on the concentrations of the extracts 
that were injected to the column (with the volume of injection of 20 µL), and the 
concentrations in breastmilk and human serum based on 8- and 5-fold concentration in the 
extracts, respectively, as shown in the same table. Table 12 shows the repeatability values (n= 
10) determined by analysing multiple aliquots of the same breastmilk and human serum 
samples on the same day and expressed as percentage standard deviations.  
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Table 12. Repeatability and recovery for the targeted compounds in breastmilk and human 
serum. 
 
Compound * Repeatability  
(n=10) 
*Recovery  
(n=6) 
** Repeatability  
(n=10) 
**Recovery  
(n=6) 
Mean ± SD 
(pM)* 
RSD 
(%) 
Mean ± SD  
(%) 
Mean ± SD 
(pM)** 
RSD  
(%) 
Mean ± SD  
(%) 
D2-S 131 ± 5.1  3.9 81.1 ± 3.21 261 ± 7.3 2.8 84.2 ± 1.64 
D3-S 261 ± 12.8 4.9 86.1 ± 2.81 692 ± 36.2 5.2 85.6 ± 4.01 
25(OH)D2-S ----  ---- 84.5 ± 4.34 1407 ± 56.4 4.0 95.1 ± 4.57 
25(OH)D3-S 172 ± 13.5 7.9 102 ± 6.25 9493 ± 971 10.2 102 ± 6.78 
* Breastmilk  
** Human serum  
 
The method was found to be precise for both milk and serum samples with percentage 
standard deviations, ranging from 2.8 to 10.2%. As shown in table 14, the mean recoveries 
calculated using the percent ratio of observed/spiked concentrations, ranged from 81.1 to 
102% (for both milk and serum samples).  
The method was then successfully applied for the determination of four D-S analogues in 
breastmilk and human serum. Figure 14 illustrates the chromatographic profiles of breastmilk 
and human serum samples.  
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Figure 15. Chromatographic profiles of the D-S analogues (underivatised forms) in 
breastmilk and in human serum. 
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As shown in Table 13, the concentrations of all D-S analogues quantified were above their 
respective LOQ values.  
 
Table 13. Concentrations (± SD) of targeted compounds in milk and serum samples. 
 
  
Compound (pM) Breastmilk Human serum 
D2-S 139 ± 5.42 495 ± 13.9  
D3-S  261 ± 12.8  704 ± 36.6 
25(OH)D2-S  ---- 1475 ± 59.0 
25(OH)D3-S 87 ± 6.9 10395 ± 106.0 
 
 
4.5 Conclusions  
Despite their poor sensitivities and specificities, colorimetric and LC-UV methods were 
previously the sole techniques available for the determination of the water-soluble forms of 
vitamin D in milk. The currently available LC-MS/MS assay methodology is limited to the 
measurement of only 25(OH)D3-S in human plasma. The method presented here is a 
significant improvement from previous analytical methods, and one that will facilitate clinical 
studies of the four sulfated forms of vitamin D. In negative ion ESI, the sulfated vitamin D 
analogues showed superior responses when compared to those obtained in positive ion mode 
(following derivatisation with PTAD), thereby enabling faster sample preparation. Co-
eluting, stable isotope labelled internal standards were used for each D-S compound, ensuring 
high accuracy and precision. The method was validated for both human serum and breastmilk 
samples, with four major sulfated vitamin D compounds being accurately quantified in serum 
and three in milk. 
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5 Chapter 5: Conclusion 
The discovery that vitamin D has many biological functions in humans beyond the skeletal 
systems has reinvigorated interest in the biological roles of this vitamin (4). Vitamin D3 (D3) 
is mainly obtained in vivo via the action of ultraviolet radiation on skin while vitamin D2 (D2) 
can be normally only obtained from food (4, 13). Vitamin D and its metabolites differ from 
each other, in terms of their biological functions; D2 compounds are less potent in man than 
D3 compounds (93, 124). The metabolite 25-hydroxyvitamin D (25(OH)D2 and/or 25(OH)D3) 
is the marker for vitamin D (123). However, 25(OH)D3 is the best indicator of the vitamin D 
status due to its higher half-life and abundance (123, 171). This major circulating form, 
25(OH)D3, can be epimerised and its measurement, along with 3-epi-25-hydroxyvitamin D3 
(3-epi-25(OH)D3) lead to an erroneous estimation of the vitamin D status (27). Dihydroxy 
metabolites (1,25-dihydroxyvitamin D (1,25(OH)2D2 and/or 1,25(OH)2D3)) and 24,25-
dihydroxyvitamin D (24,25(OH)2D2 and/or 24,25(OH)2D3) are biologically active although 
1,25(OH)2D is primarily responsible for most of the vitamin D actions (13, 93). Vitamin D 
can also occur as water-soluble sulfate forms (vitamin D-Sulfate and 25-hydroxyvitamin D-
Sulfate) (92). Little is known about this class of vitamin D, as the clinical and nutritional 
studies have mainly focused previously on the fat-soluble forms (92, 123). Their mechanisms 
and biological functions still remain to be elucidated although some have suggested that their 
potencies are equivalent to those of the non-conjugated forms (20). The ability to quantify 
individual key vitamin D forms in both nutritional and clinical samples is essential: to 
provide effective information regarding supplementation for at-risk populations; to advance 
therapeutic strategies for several clinical disorders and, to investigate their physiological roles 
(43, 93, 171).  
Immunoassays have been traditionally used for the quantification of vitamin D compounds in 
biological fluids; however, these techniques cannot differentiate vitamin D forms from each 
other and these techniques are well-known for their lack of reproducibility (123, 171). 
Despite its lack of specificity and sensitivity, liquid chromatography in conjunction with 
ultraviolet detection (LC-UV) methods have been widely used, especially for vitamin D 
analysis in fortified milk (93). Liquid chromatography-tandem mass spectrometry (LC-
MS/MS) is currently the most powerful analytical tool to measure vitamin D compounds in 
biological fluids, as a result of its high throughput efficiency, high specificity, sensitivity and 
reproducibility (171). Nevertheless, its applicability to the analysis of vitamin D compounds 
is limited due to their poor ionisation efficiency in atmospheric pressure ionisation (API) 
sources and their low levels in biological fluids such as milk (123, 171). Chemical 
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derivatisation has been used to address this problem and it has been shown to be a valuable 
strategy to enhance vitamin D compound ionisation efficiencies in API sources; Cookson-
type reagents are the most common derivatives for this class of compounds (93, 123, 171). 
Although there is a wide range of derivatising reagents, 4-phenyl-1,2,4-triazole-3,5-dione 
(PTAD) is the most popular due to its ease of availability (93). While it has been successfully 
applied to enhance the detectability of vitamin D compounds in MS/MS detections, the 
derivatisation reaction with PTAD has not been systematically optimised (93). 
Another challenge in vitamin D assays has been the extraction of these compounds from 
complex matrix. Milk samples are particularly problematic, as a result of many potential 
interfering compounds, such as sterols, triglycerides, phospholipids and other chemicals that 
have properties similar to those of vitamin D and its metabolites (32, 93, 123). Vitamin D 
compounds are tightly bound to proteins and lipids and it is necessary to disrupt this binding 
to release the vitamin prior to LC-MS/MS analysis in order generate free compound for 
analysis and to avoid matrix effects (93, 123, 171). Therefore, sample preparation for the 
analysis of vitamin D in milk has been reported to involve a quite laborious procedure and, 
even so, it does not necessarily eliminate all interfering compounds (32, 93). Protein 
precipitation (PP) has been widely used for the extraction (liberation) of vitamin D 
compounds from plasma/serum while saponification (SN) has been primarily used for their 
extractions from foodstuffs (123). These extraction procedures have often been used in 
conjunction with either solid phase extraction (SPE) or liquid-liquid extraction (LLE). This 
combination has resulted in high throughput methods. SPE is a quite laborious procedure, 
although capable of automation, and its advantages over LLE in terms of matrix effects are 
sometimes limited. It is important to note that both adequate sample preparation and 
chromatography cannot fully eliminate all interfering substances (32, 123). LC-MS/MS 
methods are particularly affected by such interfering substances. When co-eluting, these 
interfering substances can either suppress or enhance the mass spectral signal (matrix 
effects). Isotopically labelled analogues of each analyte are used as internal standards to 
correct sample losses during sample preparation and to correct matrix effects in MS detection 
(123, 171).    
The isomers, 25(OH)D3 and 3-epi-25(OH)D3 cannot be distinguished from each other solely 
by using MS/MS detection, as a result of their similar mass and fragmentation patterns. Thus, 
chromatographic separation of this critical pair is required prior to MS/MS detection (93, 
123, 171); this is a challenging task, particularly for derivatised species, as result of the 
presence of an additional peak representing each isomer following the chemical derivatisation 
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reaction (93). Available LC-MS/MS vitamin D assays in milk are unable to resolve isomers 
chromatographically and are also not able to quantify the biologically active forms that are 
found at low levels and/or the sulfate conjugated forms in this matrix. 
The primary goal of the studies presented in this thesis was to bring about advances in the 
field of vitamin D assays for milk samples by developing a highly specific and sensitive LC-
MS/MS method. Particular emphasis was placed on sample preparation procedures, LC 
separation and quantification using MS/MS detection. The selected compounds comprised: 
D2, D3, 25(OH)D2, 25(OH)D3, 3-epi-25(OH)D3, 1,25(OH)2D2, 1,25(OH)2D3, 24,25(OH)2D2, 
24,25(OH)2D3 (generally regarded as being the “fat-soluble” forms), vitamin D2-Sulfate (D2-
S), vitamin D3-Sulfate (D3-S), 25-hydroxyvitamin D2-Sulfate (25(OH)D2-S) and 25-
hydroxyvitamin D3-Sulfate (25(OH)D3-S) (the “water-soluble” forms).  
The methods presented here represent significant improvements upon existing 
methodologies. The compounds D2, D3, 25(OH)D2, 25(OH)D3, 1,25(OH)2D2, 1,25(OH)2D3, 
24,25(OH)2D2, 24,25(OH)2D3 were simultaneously measured in human and animal milk 
samples, using the method as described in Chapter 2. The metabolites 25(OH)D3 and 3-epi-
25(OH)D3 were chromatographically resolved; a necessary step to avoid potential 
overestimation of 25(OH)D3 status. The ion suppression effects from excess PTAD reagent 
were minimised, as a result of permitting longer retention times for all of the targeted 
compounds. The ESI source and MRM conditions were also adjusted for each compound in 
order to achieve the highest possible sensitivity and specificity and the Diels-Alder 
cycloaddition reaction with PTAD was thoroughly optimised. PP and SN methods were 
compared in milk samples and PP was found to be faster and simpler; it was also found 
superior in terms of extraction efficiency. PP in conjunction with LLE was further optimised. 
The accuracy of the method was ensured by using isotopically labelled internal standards for 
each targeted compound. A combination of the above mentioned optimisations, enhancement 
of the MS parameters and the use of appropriate chromatography resulted in a very sensitive, 
selective, and accurate method for the determination of the targeted compounds at low levels. 
This method was successfully applied for the quantification of vitamin D compounds in milk 
and it is anticipated that this method can easily be adapted for other complex matrices such as 
human serum. This method was then applied to investigate the effect of pasteurisation on the 
content of the major vitamin D forms (D2, D3, 25(OH)D2 and 25(OH)D3) in breastmilk, as 
described in the chapter 3. In this study, it was confirmed that the vitamin D content in milk 
is significantly low and it does not satisfy the vitamin D’s requirements for either term or 
preterm infants. Pasteurisation was demonstrated to be a potential source of vitamin D 
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degradation since losses were observed after this thermal procedure. Pasteurisation is a 
common procedure adopted by breastmilk banks to ensure its safety for infant consumption. 
Therefore, the findings reported here will assist health care professionals in providing 
appropriate vitamin D supplementation for infants where necessary. Such findings may also 
prove useful for directing improvements in milk pasteurisation procedures, which may reduce 
losses of vitamin D content in donor breastmilk samples. 
This LC-MS/MS method was initially developed for the analysis of both non-conjugated and 
the sulfated forms. However, the method as described in chapter 2 proved inadequate to 
determine the sulfated forms, hence, it was necessary to develop a new strategy to determine 
D2-S, D3-S, 25(OH)D2-S and 25(OH)D3-S in biological samples. These sulfate conjugate 
compounds (without derivatisation), when quantified in negative ion ESI, gave a superior MS 
signal response when compared to the PTAD derivatised forms of the same compounds using 
positive ion mode. This observation resulted in a significant simplification of the sample 
preparation procedure, as the derivatisation step proved to be unnecessary. Since the 
difference between conjugated and non-conjugated forms is the ionisation efficiency, the 
same stationary phase (C18) was used for all targeted compounds. However, formic acid (at 
pH 3) was used to facilitate the protonation for derivatised forms in positive mode and 
ammonium formate (at pH 7) was used to facilitate the de-protonation for non-derivatised 
forms in negative mode. The method was developed and validated to quantify the four major 
sulfated forms and is described in Chapter 4. The applicability of the method was 
demonstrated in samples of both human serum and breastmilk.  
Overall, the studies reported in this thesis have resulted in the development of highly specific 
and sensitive LC-MS/MS methods for the successful determination of twelve key vitamin D 
compounds in milk. These methods will therefore enable researchers to study more precisely 
the activities and functions of each vitamin D analogue and the total amount (and activity) of 
vitamin D in milk and other biological fluids which is of key importance to investigate links 
between vitamin D and clinical disorders.  
As mentioned previously, LC-MS/MS has become increasingly important for the analysis 
vitamin D and its metabolites in biological fluids. While there is a continuing trend towards 
the development of new derivatising reagents, a parallel future study is required to improve 
API sources. It will allow the measurement of dihydroxy-vitamin D metabolites at low levels 
in biological fluids; eliminating the use of derivatisation reactions and then simplifying 
sample preparation procedures. Further research work is additionally required to advance the 
automation of sample preparation procedures, in conjunction with the development of more 
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specific LC methods, in order to fulfil the demand for high-throughput analysis techniques, 
and to reduce manual handling errors and biological hazards as well as avoiding the co-
elution of vitamin D isomers. The trend towards more rigorous clean-up procedures is 
necessary in order to achieve high selectivity and a precise quantification of the dihydroxy-
vitamin D metabolites at picomolar levels. Further studies are also necessary to reduce 
sample and extraction solvent volumes. Such an approach will certainly assist in minimising 
the impact of chemical residues in the environment and reduce associated costs. 
Human milk banks routinely use pasteurisation and it is a necessary step to ensure its safety 
for consumption. Further studies are necessary to evaluate whether vitamin D losses could be 
also associated with compound adsorption and/or fat adsorption to the pasteurisation 
container. Thus, the findings obtained in this thesis will be useful to assist such future work.  
There are many studies regarding the physiological roles of sulfated forms of vitamin D; but 
their roles remain controversial. Further research work is required to better understand this 
class of vitamin D compounds. It would therefore be of clinical interest to investigate 
whether 25(OH)D3-S could be epimerised, as it could be a potential vitamin D marker. Also, 
it would be of greatest interest to investigate whether there are dihydroxy-vitamin D 
compounds present as the respective sulfate conjugate. The method as presented in this thesis 
is specific for sulfated forms and hence it will be useful for such investigations on the 
biological function of these conjugates. 
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